Antibodies that bind il-13 and antibodies that bind TSLP in combination with hyaluronidase or a variant thereof

Abstract

Described herein are compositions and combinations comprising an antibody or antigen binding fragment thereof that binds interleukin (IL)- 13, an antibody or antigen binding fragment thereof that binds thymic stromal lymphopoietin (TSLP), and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient by administering such compositions and combinations.

Description

AOJ-012PCAOE-0106WOANTIBODIES THAT BIND IL-13 AND ANTIBODIES THAT BIND TSLP IN COMBINATION WITH HYALURONIDASE OR A VARIANT THEREOFCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 708,908 (filed October 18, 2024) and U.S. Provisional Application No. 63 / 827,210 (filed June 20, 2025), both of which are incorporated by reference herein in their entirety.SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML copy, created on October 16, 2025, is named AOJ-012PC_SL.xml and is 620,754 bytes in size.BACKGROUND

[0003] Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine produced in response to pro-inflammatory stimuli. TSLP has been discovered to promote allergic inflammatory responses primarily through its activity on dendritic and mast cells. Human TSLP expression has been reported to be increased in asthmatic airways correlating to disease severity. In addition, TSLP protein levels are detectable in the concentrated bronchoalveolar lavage (BAL) fluid of asthma patients and other patients suffering from allergic disorders. In addition, TSLP has also been found to promote fibrosis.

[0004] TSLP binds to a heterodimeric receptor consisting of the TSLP receptor (TSLPR) and an IL-7 receptor a chain (IL-7Ra) in dendritic cells, thereby activating the dendritic cells. Upon activation, the dendritic cells express inflammatory chemokines such as thymus and activation regulated chemokine (TARC (CCL17)), macrophage-derived chemo kine (MDC (CCL22)), and the like.

[0005] Activation of dendritic cells by TSLP through the TSLP receptor is associated with disease pathology, including allergic inflammatory diseases, such as asthma, and autoimmune disease, such as systemic sclerosis.

[0006] Meanwhile, interleukin (IL)- 13 is a T helper cell subclass 2 (Th2) cytokine and belongs to a family of type I cytokines, exhibiting pleiotropic effects across multiple cellular pathways. IL-13 is involved in the differentiation of naive T cells into Th2 cells. IL-13 promotes B-cell proliferation and induces immunoglobulin isotype class switching to IgG4AOJ-012PCAOE-0106WO and IgE when co-stimulated with CD40 / CD40L. It also up-regulates FcsRI, and thus, helps in IgE priming of mast cells. In monocytes / macrophages, IL-13 up-regulates expression of CD23 and MHC class I and class II antigens, down-regulates the expression of GDI 4, inhibits antibody-dependent cytotoxicity, and promotes eosinophil survival, activation, and recruitment. IL- 13 also manifests important functions on nonhematopoietic cells, such as smooth muscle cells, epithelial cells, endothelial cells, and fibroblast cells. IL- 13 enhances proliferation and cholinergic-induced contractions of smooth muscles. In epithelial cells, IL- 13 is a potent inducer of chemokine production, alters mucociliary differentiation, decreases ciliary beat frequency of ciliated epithelial cells, and results in goblet cell metaplasia. In endothelial cells, IL-13 is a potent inducer of vascular cell adhesion molecule 1 (VCAM-1), which is important for recruitment of eosinophils. In epithelial keratinocytes, IL- 13 reduces the expression of barrier integrity molecules, such as filaggrin and loricrin, while stimulating CCL26 and CCL2 secretion responsible for the recruitment of several inflammatory cells of myeloid lineages. In human dermal fibroblasts, IL- 13 induces type 1 collagen synthesis in human dermal fibroblasts.

[0007] The inhibition of IL-13 may be used to treat or prevent inflammatory diseases and conditions, such as those related to elevated levels of IgE, including but not limited to asthma, allergic rhinitis, urticaria, and allergic or atopic dermatitis. Thus, the development of potent and specific inhibitors of IL- 13, for example, inhibitors that remain active for longer terms when administered to subjects, are needed for the prevention and / or treatment IL- 13- and IgE-mediated diseases or conditions.

[0008] Accordingly, there is a need in the art for antagonists to IL- 13 and TSLP for preventing and treating diseases in which IL-13 and TSLP are involved in the disease pathology, such as inflammatory and fibrotic disorders.

[0009] In addition, there is a need in the art for improved therapeutics that target both TSLP and IL-13, such as a combination of antibodies wherein, for example, one or more of the antibodies remains active for a longer term (i.e., has a longer half-life) as compared to another anti-TSLP antibody (e.g., tezepelumab) or anti-IL-13 antibody (e.g., lebrikizumab) when administered to a subject. There is also a need for delivering relatively large doses of these antibodies subcutaneously.AOJ-012PCAOE-0106WOSUMMARY

[0010] The present disclosure provides compositions and combinations comprising antibodies to TSLP, or antigen binding fragments thereof, such as recombinant human antibodies, antibodies that specifically bind interleukin (IL)-13, or antigen binding fragments thereof, and a hyaluronidase or a variant thereof. Also featured are methods of treating diseases in which human TSLP and IL- 13 are involved in disease pathology by administering to a subject an antibody, or antigen fragment thereof, that binds TSLP, an antibody, or antigen binding fragment thereof, that binds IL- 13, and a hyaluronidase or variant thereof. Diseases that can be treated according to the methods described herein include atopic dermatitis and asthma, among others. The antibodies of the disclosure can include Fc modifications and exhibit longer half-lives than an otherwise identical antibody that does not include the Fc modification, for example, certain anti-TSLP or anti-IL-13 antibodies known in the art.

[0011] In a first aspect, the invention provides a composition comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL-13, and a hyaluronidase or variant thereof.

[0012] In another aspect, the invention provides a composition comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL-13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding fragment thereof, that binds TSLP comprises: a) a variable heavy (VH) chain sequence having three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3; and b) a variable light (VL) chain sequence having three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3; wherein the antibody, or antigen binding fragment thereof, that binds TSLP comprises: (i) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 21 and 24; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27; (ii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-LI comprising the sequence set forth in any one of SEQ ID NOs: 19 and 22; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS; and aAOJ-012PCAOE-0106WOCDR-L3 comprising the sequence set forth in SEQ ID NO: 30; (iii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11 , and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 310 and 324; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 351; or (iv) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 315 and 331; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 355.

[0013] In another aspect, the invention provides a composition comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP or TSLPR, an isolated antibody, or antigen binding fragment thereof, that binds IL- 13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises: a) a variable heavy (VH) chain sequence having three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3; and b) a variable light (VL) chain sequence having three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3; wherein the antibody that binds IL-13 comprises: (i) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285; or (ii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 284 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.AOJ-012PCAOE-0106WO

[0014] In another aspect, the invention provides a combination comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL- 13, and a hyaluronidase or variant thereof.

[0015] In another aspect, the invention provides a combination comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL- 13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding fragment thereof, that binds TSLP comprises: a) a variable heavy (VH) chain sequence having three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3; and b) a variable light (VL) chain sequence having three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3; wherein the antibody, or antigen binding fragment thereof, that binds TSLP comprises: (i) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 21 and 24; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27; (ii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 19 and 22; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 30; (iii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 310 and 324; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 351; or (iv) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 315 and 331; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO:AOJ-012PCAOE-0106WO

[0016] In another aspect, the invention provides a combination comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP or TSLPR, an isolated antibody, or antigen binding fragment thereof, that binds IL-13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises: a) a variable heavy (VH) chain sequence having three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3; and b) a variable light (VL) chain sequence having three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3; wherein the antibody that binds IL-13 comprises: (i) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285; or (ii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 284 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0017] In one aspect, provided herein is a method of treating an inflammatory disorder or disease in a human patient comprising administering to the patient an isolated antibody, or antigen binding fragment thereof, that binds TSLP, comprising: a) a variable heavy (VH) chain sequence having three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3; and b) a variable light (VL) chain sequence having three light chain CDR sequences, CDR- Ll, CDR-L2, and CDR-L3; wherein the antibody, or antigen binding fragment thereof, that binds TSLP comprises: (i) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 21 and 24; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27; (ii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR- H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 1 1, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1AOJ-012PCAOE-0106WO comprising the sequence set forth in any one of SEQ ID NOs: 19 and 22; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 30; (iii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 310 and 324; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 351; or (iv) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 315 and 331; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 355; an isolated antibody, or antigen binding fragment thereof, that binds IL-13; and a hyaluronidase or variant thereof.

[0018] In some embodiments, the isolated antibody, or antigen binding fragment thereof, that binds IL-13 comprises a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of an antibody selected from lebrikizumab, tralokinumab, romilkimab, cendakimab, and anrukinzumab.

[0019] In some embodiments, the isolated antibody, or antigen binding fragment thereof, that binds IL- 13 comprises: a) a VH chain sequence having three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3; and b) a VL chain sequence having three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, wherein the isolated antibody, or antigen binding fragment thereof, that binds IL- 13 comprises: (i) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285; or (ii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275: a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising theAOJ-012PCAOE-0106WO sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 284 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0020] In one aspect, provided herein is a method of treating an inflammatory disorder or disease in a human patient comprising administering to the patient an isolated antibody, or antigen binding fragment thereof, that binds TSLP or TSLPR; a hyaluronidase or variant thereof; and an isolated antibody, or antigen binding fragment thereof, that binds IL- 13, comprising: a) a variable heavy (VH) chain sequence having three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3; and b) a variable light (VL) chain sequence having three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3; wherein the antibody that binds IL- 13 comprises: (i) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285; or (ii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 284 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0021] In some embodiments, the isolated antibody, or antigen binding fragment thereof, that binds TSLP comprises a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of an antibody selected from tezepelumab, GR2002 (described in US Patent Application Publication No. US20240132581, which is incorporated herein by reference), TQC2731 (also known as BSL045B and bosakitug, described in US Patent Application Publication No. US20220289833, which is incorporated herein by reference), solrikitug, hu23bl2, 43B 1- H2L2, and 43B1-H6L1.

[0022] In some embodiments, the isolated antibody, or antigen binding fragment thereof, that binds TSLPR comprises a CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR- L3 of ASP7266 (also known as UPB-101 and verekitug).

[0023] In some embodiments, the isolated antibody, or antigen binding fragment thereof, that binds TSLP comprises: a) a VH chain sequence having three heavy chain CDRAOJ-012PCAOE-0106WO sequences, CDR-H1, CDR-H2, and CDR-H3; and b) a VL chain sequence having three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, wherein the isolated antibody, or antigen binding fragment thereof, that binds TSLP comprises: (i) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 21 and 24; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27; (ii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 19 and 22; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 30; (iii) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR- H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 310 and 324; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 351 ; or (iv) a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 315 and 331; a CDR-E2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 355.

[0024] In some embodiments, (a) the antibody, or antigen binding fragment thereof, that binds TSLP comprises: a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 21 and 24; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27; and (b) the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a CDR-H1AOJ-012PCAOE-0106WO comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278: a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0025] In some embodiments, (a) the antibody, or antigen binding fragment thereof, that binds TSLP comprises: a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 19 and 22; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 30; and (b) the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275: a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0026] In some embodiments, (a) the antibody, or antigen binding fragment thereof, that binds TSLP comprises: a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 310 and 324; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 351; and (b) the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.AOJ-012PCAOE-0106WO

[0027] In some embodiments, (a) the antibody, or antigen binding fragment thereof, that binds TSLP comprises: a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 315 and 331; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 355; and (b) the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278: a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0028] In some embodiments, (a) the antibody, or antigen binding fragment thereof, that binds TSLP comprises: a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 21 and 24; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27; and (b) the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275: a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 284 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0029] In some embodiments, (a) the antibody, or antigen binding fragment thereof, that binds TSLP comprises: a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 19 and 22; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 25 or the amino acid sequenceAOJ-012PCAOE-0106WODVS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 30; and (b) the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 284 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0030] In some embodiments, (a) the antibody, or antigen binding fragment thereof, that binds TSLP comprises: a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 310 and 324; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 351; and (b) the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 284 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0031] In some embodiments, (a) the antibody, or antigen binding fragment thereof, that binds TSLP comprises: a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 315 and 331; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 355; and (b) the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 273, 274, and 275; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 276, 277, and 278: a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 279 and 280; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 281 and 282; a CDR-L2AOJ-012PCAOE-0106WO comprising the sequence set forth in SEQ ID NO: 284 or the amino acid sequence LAS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0032] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a heavy chain variable domain (VH) sequence comprising the amino acid sequence set forth in any one of SEQ ID NOs: 32-36 and 418. In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34.

[0033] In some embodiments, the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286.

[0034] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a light chain variable domain (VL) sequence comprising the amino acid sequence set forth in any one of SEQ ID NOs: 37-45 and 361-396. In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VL sequence comprising the amino acid sequence set forth in any one of SEQ ID NOs: 41, 43, 374, and 380.

[0035] In some embodiments, the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VL sequence comprising the amino acid sequence set forth in any one of SEQ ID NOs: 287-288.

[0036] In some embodiments, (a) the antibody, or antigen binding fragment thereof, that binds TSLP comprises: (i) a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 32; (ii) a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 33; or (iii) a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and / or (iv) a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 41; (v) a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 43; (vi) a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 374; or (vii) a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 380; and / or (b) the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises: (i) a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286; and / or (ii) a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 287; or (iii) a VL sequence comprising the amino acid sequence set forth SEQ ID NO: 288.

[0037] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQAOJ-012PCAOE-0106WOID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 41.

[0038] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 43.

[0039] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 374.

[0040] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 380.

[0041] In some embodiments, the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 287.

[0042] In some embodiments, the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 288.

[0043] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 41; and the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 287.

[0044] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 41; and the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 288.AOJ-012PCAOE-0106WO

[0045] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 43; and the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 287.

[0046] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 43; and the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a VH sequence comprising the amino acid sequence set in SEQ ID NO: 286; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 288.

[0047] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 374; and the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 287.

[0048] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 374; and the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 288.

[0049] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 380; and the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 287.

[0050] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 380; and the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VHAOJ-012PCAOE-0106WO sequence comprising the amino acid sequence set forth in SEQ ID NO: 286; and a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 288.

[0051] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL-13 is a humanized, human, or chimeric antibody.

[0052] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL- 13 is a humanized antibody.

[0053] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a heavy chain human constant region of a class selected from IgG, IgA, IgD, IgE, and IgM.

[0054] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a human Fc region, and the human Fc region comprises a human heavy chain constant region of the class IgG and a subclass selected from IgGl, IgG2, IgG3, and IgG4.

[0055] In some embodiments, the human Fc region of the antibody, or antigen binding fragment thereof, that binds TSLP and / or the human Fc region of the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a human IgGl Fc region.

[0056] In some embodiments, the human Fc region of the antibody, or antigen binding fragment thereof, that binds TSLP and / or the human Fc region of the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a human IgG4 Fc region.

[0057] In some embodiments, the human Fc region of the antibody, or antigen binding fragment thereof, that binds TSLP and / or the human Fc region of the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a human IgG2 Fc region.

[0058] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a heavy chain comprising a constant heavy chain sequence selected from the amino acid sequences set forth in any one of SEQ ID NOs: 47-270.

[0059] In some embodiments, the heavy chain of the antibody, or antigen binding fragment thereof, that binds TSLP and / or the heavy chain of the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a constant heavy chain sequence selected from an amino acid sequence set forth in any one of SEQ ID NOs: 61, 79, 173, and 180.AOJ-012PCAOE-0106WO

[0060] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a light chain comprising a constant light chain sequence set forth in SEQ ID NO: 46 or 495.

[0061] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a light chain comprising a human lambda light chain constant region. In some embodiments, the human lambda light chain constant region comprises a sequence set forth in any one of SEQ ID NOs: 495-498. In some embodiments, the human lambda light chain constant region comprises a sequence set forth in SEQ ID NO: 495.

[0062] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a light chain comprising a human lambda light chain constant region and / or the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a light chain comprising a human kappa light chain constant region.

[0063] In some embodiments, the light chain of the antibody, or antigen binding fragment thereof, that binds TSLP comprises a constant light chain sequence set forth in SEQ ID NO: 495.

[0064] In some embodiments, the light chain of the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a constant light chain sequence set forth in SEQ ID NO: 46.

[0065] In some embodiments, the antibody that binds IL- 13 comprises a heavy chain sequence set forth in SEQ ID NO: 486 or 487 and a light chain sequence set forth in SEQ ID NO: 488. In some embodiments, the antibody that binds IL-13 comprises a heavy chain sequence set forth in SEQ ID NO: 486 and a light chain sequence set forth in SEQ ID NO: 488. The heavy chain sequence of SEQ ID NO: 486 contains a C-terminal lysine, which may be cleaved off during manufacture or after administration, resulting in the heavy chain sequence of SEQ ID NO: 487. In some embodiments, the antibody that binds IL-13 comprises a heavy chain sequence set forth in SEQ ID NO: 487 and a light chain sequence set forth in SEQ ID NO: 488.

[0066] In some embodiments, the antibody that binds TSLP comprises a heavy chain sequence set forth in SEQ ID NO: 499 or 501 and a light chain sequence set forth in SEQ ID NO: 500. In some embodiments, the antibody that binds TSLP comprises a heavy chain sequence set forth in SEQ ID NO: 499 and a light chain sequence set forth in SEQ ID NO: 500. The heavy chain sequence of SEQ ID NO: 499 contains a C-terminal lysine, which mayAOJ-012PCAOE-0106WO be cleaved off during manufacture or after administration, resulting in the heavy chain sequence of SEQ ID NO: 501. In some embodiments, the antibody that binds TSLP comprises a heavy chain sequence set forth in SEQ ID NO: 501 and a light chain sequence set forth in SEQ ID NO: 500.

[0067] In some embodiments, the antibody that binds TSLP is Antibody 5 and the antibody that binds IL- 13 is Construct 133.

[0068] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP is an antibody having a VH sequence and a VL sequence from the same row of TABLE 4 (z.e., a VH sequence and VL sequence from a single antibody in TABLE 4) and the antibody that binds IL-13 is Construct 133.

[0069] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP is an antibody having a VH sequence and a VL sequence from the same row of TABLE 6 (z'.e., a VH sequence and VL sequence from a single antibody in TABLE 6) and the antibody that binds IL- 13 is Construct 133.

[0070] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP is an antibody having a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 from the same row of TABLE 3 (i.e., having six CDRs from a single antibody in TABLE 3) and the antibody that binds IL-13 is Construct 133.

[0071] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP is an antibody having a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 from the same row of TABLE 5 (i.e., having six CDRs from a single antibody in TABLE 5) and the antibody that binds IL-13 is Construct 133.

[0072] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a heavy chain constant domain having a means for increasing the half-life of the antibody.

[0073] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises an Fc region comprising one or more amino acid substitutions, wherein the one or more amino acid substitutions result in an increase in one or more of antibody half-life, ADCC activity, ADCP activity, or CDC activity compared with the Fc without the one or more substitutions.

[0074] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL- 13AOJ-012PCAOE-0106WO comprises an Fc region comprising one or more amino acid substitutions, wherein the one or more amino acid substitutions result in a decrease in one or more of, ADCC activity, ADCP activity or CDC activity compared to an antibody comprising a wild-type Fc region.

[0075] In some embodiments, the one or more amino acid substitutions is selected from the group consisting of S228P. T250Q, M252Y, S254T, T256E, T256D, H285D, T307A, T307Q, T307R, T307W, L309D, Q411H, Q311V, A378V, E380A, M428L, N434A, N434S, N297A, D265A, L234A, L235A, and N434W (or, e.g., L235A, L236A, L239A, L240A, M253Y, S255T, T257E, M257Y, S259T, or T261E using direct numbering); optionally, wherein the one or more amino acid substitutions comprises a plurality of amino acid substitutions selected from the group consisting of M428L / N434S (LS), M252Y / S254T / T256E (YTE) using EU numbering or M257Y / S259T / T261E (YTE) using direct numbering or M253Y / S255T / T257E (YTE) using direct numbering, T250Q / M428L, T307A / E380A / N434A, T256D / T307Q (DQ), T256D / T307W (DW), M252Y / T256D (YD), T307Q / Q311V / A378V (QVV), T256D / H285D / T307R / Q311V / A378V (DDRVV), L309D / Q311H / N434S (DHS), S228P / L235E (SPLE), L234A / L235A (LALA) using EU numbering or L239A / L240A (LALA) using direct numbering or L235A / L236A (LALA) using direct numbering, M428L / N434A (LA), L235A / G237A (LAGA), L234A / L235A / G237A (LALAGA), L234A / L235A / P329G (LALAPG), D265A / YTE, LALA / YTE, LAGA / YTE, LALAGA / YTE, LALAPG / YTE, N297A / LS, D265A / LS, LALA / LS, LALAGA / LS, LALAPG / LS, N297A / DHS, D265A / DHS, LALA / DHS, LAGA / DHS, LALAGA / DHS, LALAPG / DHS, SP / YTE, SPLE / YTE, SP / LS, SPLE / LS, SP / DHS, SPLE / DHS, N297A / LA, D265A / LA, LALA / LA, LAGA / LA, LALAGA / LA, LALAPG / LA, N297A / N434A, D265A / N434A, LALA / N434A, LAGA / N434A, LALAGA / N434A, LALAPG / N434A, N297A / N434W, D265A / N434W, LALA / N434W, LAGA / N434W, LALAGA / N434W, LALAPG / N434W, N297A / DQ, D265A / DQ, LALA / DQ, LAGA / DQ, LALAGA / DQ, LALAPG / DQ, N297A / DW, D265A / DW, LALA / DW, LAGA / DW, LALAGA / DW, LALAPG / DW, N297A / YD, D265A / YD, LALA / YD, LAGA / YD, LALAGA / YD, LALAPG / YD, T307Q / Q311V / A378V (QVV), N297A / QVV, D265A / QVV, LALA / QVV, LAGA / QVV, LALAGA / QVV, LALAPG / QVV, DDRVV, N297A / DDRVV, D265A / DDRVV, LALA / DDRVV, LAGA / DDRVV, LALAGA / DDRVV, and LALAPG / DDRVV. In some embodiments, the one or more amino acid substitutions is selected from the group consisting of LS, YTE, T250Q / M428L, T307A / E380A / N434A, DQ, DW, YD, QVV, DHS, LA, D265A / YTE, LALA / YTE, LAGA / YTE, LALAGA / YTE, LALAPG / YTE, N297A / LS, D265A / LS, LALA / LS,AOJ-012PCAOE-0106WOLALAGA / LS, LALAPG / LS, N297A / DHS, D265A / DHS, LALA / DHS, LAGA / DHS, LALAGA / DHS, LALAPG / DHS, SP / YTE, SPLE / YTE. SP / LS, SPLE / LS, SP / DHS, SPLE / DHS, N297A / LA, D265A / LA, LALA / LA, LAGA / LA, LALAGA / LA, LALAPG / LA, N297A / DQ, D265A / DQ, LALA / DQ, LAGA / DQ, LALAGA / DQ, LALAPG / DQ, N297A / DW, D265A / DW, LALA / DW, LAGA / DW, LALAGA / DW, LALAPG / DW, N297A / YD, D265A / YD, LALA / YD, LAGA / YD, LALAGA / YD, LALAPG / YD, N297A / QVV, D265A / QVV, LALA / QVV, LAGA / QVV, LALAGA / QVV, and LALAPG / QVV.

[0076] In some embodiments, the Fc region of the antibody that binds TSLP and / or the antibody that binds IL- 13 comprises LALA / YTE substitutions.

[0077] Although the EU numbering system is typically used to identify the positions of the various Fc mutations described herein, direct numbering can also be used. For example, in certain embodiments, an antibody described herein comprises an Fc region with YTE mutations at positions 253 / 255 / 257 or 257 / 259 / 261, respectively. In certain embodiments, an antibody described herein comprises an Fc region with LALA mutations at positions 235 / 236 or 239 / 240, respectively. In certain embodiments, an antibody described herein comprises an Fc region with YTE mutations at positions 253 / 255 / 257 or 257 / 259 / 261, respectively and with LALA mutations at positions 235 / 236 or 239 / 240, respectively. In certain embodiments, the TSLP antibody described herein comprises an Fc region comprising YTE mutations at positions 257 / 259 / 261, respectively and LALA mutations at positions 239 / 240, respectively. In certain embodiments, the TSLP antibody described herein comprises the VH and VL of Antibody 5 and an Fc region comprising YTE mutations at positions 257 / 259 / 261, respectively and with LALA mutations at positions 239 / 240, respectively. In certain embodiments, the IL- 13 antibody described herein comprises an Fc region comprising YTE mutations at positions 253 / 255 / 257, respectively and LALA mutations at positions 235 / 236, respectively. In certain embodiments, the IL- 13 antibody described herein comprises the VH and VL of Construct 133 and an Fc region comprising YTE mutations at positions 253 / 255 / 257, respectively and with LALA mutations at positions 235 / 236, respectively.

[0078] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34, a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 41, and a human IgGl Fc region comprising LALA and YTE mutations; and the antibody that binds IL- 13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286, a VL sequence comprising the amino acid sequence set forth in SEQ ID NO:AOJ-012PCAOE-0106WO287, and a human IgGl Fc region comprising LALA and YTE mutations. In some embodiments, the antibody that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34, a constant heavy chain sequence comprising the amino acid sequence set forth SEQ ID NO: 173 and / or a constant heavy chain sequence comprising the amino acid sequence set forth SEQ ID NO: 61, a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 41, and a constant light chain sequence comprising the amino acid sequence set forth in SEQ ID NO: 495; and the antibody that binds IL-13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286, a constant heavy chain sequence comprising the amino acid sequence set forth SEQ ID NO: 173 and / or a constant heavy chain sequence comprising the amino acid sequence set forth SEQ ID NO: 61, a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 287, and a constant light chain sequence comprising the amino acid sequence set forth in SEQ ID NO: 46. In some embodiments, the antibody that binds TSLP comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 34, a constant heavy chain sequence comprising the amino acid sequence set forth SEQ ID NO: 173, a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 41, and a constant light chain sequence comprising the amino acid sequence set forth in SEQ ID NO: 495; and the antibody that binds IL- 13 comprises a VH sequence comprising the amino acid sequence set forth in SEQ ID NO: 286, a constant heavy chain sequence comprising the amino acid sequence set forth SEQ ID NO: 173, a VL sequence comprising the amino acid sequence set forth in SEQ ID NO: 287, and a constant light chain sequence comprising the amino acid sequence set forth in SEQ ID NO: 46. A C-terminal lysine is present in SEQ ID NO: 173, which may be cleaved off during manufacture or after administration, resulting in the sequence of SEQ ID NO: 61. Accordingly, a composition comprising an antibody that binds TSLP and / or an antibody that binds IL- 13 comprising the constant heavy chain sequence of SEQ ID NO: 173 that is administered to a subject may comprise antibodies having the constant heavy chain sequence set forth in SEQ ID NO: 173 or SEQ ID NO: 61, or a mixture thereof (e.g., a mixture of antibodies containing either a constant heavy chain sequence of SEQ ID NO: 173 or a constant heavy chain sequence of SEQ ID NO: 61 and / or antibodies containing both constant heavy chain sequences (e.g., in an antibody containing two constant heavy chain sequences)).

[0079] In some embodiments, the antibody that binds TSLP comprises a heavy chain sequence comprising the amino acid sequence set forth SEQ ID NO: 499 and / or 501 and a light chain sequence comprising the amino acid sequence set forth in SEQ ID NO: 500; andAOJ-012PCAOE-0106WO the antibody that binds IL- 13 comprises a heavy chain sequence comprising the amino acid sequence set forth SEQ ID NO: 486 and / or 487 and a light chain sequence comprising the amino acid sequence set forth in SEQ ID NO: 488. In some embodiments, the antibody that binds TSLP comprises a heavy chain sequence comprising the amino acid sequence set forth SEQ ID NO: 499 and a light chain sequence comprising the amino acid sequence set forth in SEQ ID NO: 500; and the antibody that binds IL- 13 comprises a heavy chain sequence comprising the amino acid sequence set forth SEQ ID NO: 486 and a light chain sequence comprising the amino acid sequence set forth in SEQ ID NO: 488. The C-terminal lysine in SEQ ID NO: 499 and / or SEQ ID NO: 486 may not be present if cleavage occurs during manufacture or after administration (which would result in the heavy chain sequence of SEQ ID NO: 501 and / or SEQ ID NO: 487, respectively).

[0080] In some embodiments, the antibody that binds TSLP is Antibody 5 and the antibody that binds IL- 13 is lebrikizumab, tralokinumab, romilkimab, cendakimab, or anrukinzumab.

[0081] In some embodiments, the antibody that binds TSLP is tezepelumab, GR2002, TQC2731, solrikitug, hu23bl2, 43B1-H2L2, or 43Bl-H6Lland the antibody that binds IL- 13 is Construct 133.

[0082] In some embodiments, the antibody that binds TSLPR is ASP7266 (also known as UPB-101 and verekitug).

[0083] In some embodiments, the Fc region of the antibody, or antigen binding fragment thereof, that binds TSLP and / or the Fc region of the antibody, or antigen binding fragment thereof, that binds IL-13 binds to Neonatal Fc receptor (FcRn).

[0084] In some embodiments, the Fc region of the antibody, or antigen binding fragment thereof, that binds TSLP and / or the Fc region of the antibody, or antigen binding fragment thereof, that binds IL-13 binds an FcRn with higher affinity at pH 6.0 compared to an antibody comprising a wild-type Fc region.

[0085] In some embodiments, the Fc region of the antibody, or antigen binding fragment thereof, that binds TSLP and / or the Fc region of the antibody, or antigen binding fragment thereof, that binds IL- 13 binds to FcRn with a KD of <1 x 10-7 M at pH 6.0.

[0086] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL- 13 is a monoclonal antibody.AOJ-012PCAOE-0106WO

[0087] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP binds a TSLP sequence set forth in the amino acid sequence of any one of SEQ ID NOs: 271 -272.

[0088] In some embodiments, the antibody, or antigen binding fragment thereof, that binds IL- 13 binds an IL- 13 sequence set forth in the amino acid sequence of any one of SEQ ID NOs: 291-294 (e.g., SEQ ID NO: 291 or SEQ ID NO: 292).

[0089] In some embodiments, any of the isolated antibodies, or antigen binding fragments thereof, disclosed herein are for use in the treatment of an inflammatory disorder or disease.

[0090] In some embodiments, any of the isolated antibodies, or antigen binding fragments thereof, disclosed herein are for use in the treatment of atopic dermatitis (AD).

[0091] In some embodiments, the treatment reduces disease severity in a patient and wherein disease severity is assessed by an atopic dermatitis disease severity outcome measure.

[0092] In some embodiments, any of the isolated antibodies, or antigen binding fragments thereof, disclosed herein are for use in the treatment of asthma, chronic sinusitis with nasal polyps; Chronic Rhinosinusitis without Nasal Polyps (CRSsNP); eosinophilic esophagitis (EoE); an Eosinophilic gastrointestinal disorder or disease (EGID), such as Eosinophilic Gastritis (EoG), Eosinophilic Enteritis (EoN), Eosinophilic Colitis (EoC), or Eosinophilic Gastroenteritis (EGE); Churg-Strauss syndrome / Eosinophilic granulomatosis with polyangiitis (EGPA); Prurigo Nodularis (PN); Chronic Spontaneous Urticaria (CSU); Chronic Pruritis of Unknown Origin (CPUO); Bullous Pemphigoid (BP); Cold Inducible Urticaria (ColdU); Allergic Fungal Rhinosinusitis (AFRS); Allergic Bronchopulmonary Aspergillosis (AB PA); Chronic Obstructive Pulmonary Disease (COPD); an inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis; lupus; rheumatoid arthritis (RA); psoriasis; hidradenitis suppurativa; celiac disease; idiopathic pulmonary fibrosis; alopecia areata; or systemic sclerosis.

[0093] In some embodiments, any of the isolated antibodies, or antigen binding fragments thereof, disclosed herein are for use in the treatment of asthma.

[0094] In some embodiments, any of the isolated antibodies, or antigen binding fragments thereof, disclosed herein are for use in the treatment of COPD.

[0095] In another aspect, provided herein is an isolated polynucleotide or set of polynucleotides encoding an isolated antibody disclosed herein, a VH thereof, a VL thereof, aAOJ-012PCAOE-0106WO light chain thereof, a heavy chain thereof, or an antigen-binding portion thereof, and optionally, wherein the polynucleotide or set of polynucleotides comprises cDNA.

[0096] In another aspect, provided herein is a vector or set of vectors comprising the polynucleotide or set of polynucleotides disclosed herein.

[0097] In another aspect, provided herein is a host cell comprising the polynucleotide or set of polynucleotides or the vector or set of vectors disclosed herein.

[0098] In another aspect, provided herein is a method of producing one or more of the isolated antibodies, or antigen binding fragments thereof, disclosed herein, the method comprising expressing one or more of the antibodies within the host cell disclosed herein and isolating the one or more expressed antibodies.

[0099] In another aspect, provided herein is a pharmaceutical composition comprising any of the isolated antibodies, or antigen binding fragments thereof, disclosed herein and a pharmaceutically acceptable excipient (z.e., a pharmaceutical composition comprising an antibody, or antigen binding fragment thereof, that binds to TSLP and / or an antibody, or antigen binding fragment thereof, that binds to IL- 13). In some embodiments, the pharmaceutical composition further comprises a hyaluronidase or a variant thereof.

[0100] In another aspect, provided herein is a kit comprising any of the isolated antibodies, or antigen binding fragments thereof, disclosed herein (e.g., a kit comprising an antibody, or antigen binding fragment thereof, that binds to TSLP and an antibody, or antigen binding fragment thereof, that binds to IL- 13) or the pharmaceutical composition disclosed herein and instructions for use. In some embodiments, the kit further comprises a hyaluronidase or a variant thereof.

[0101] In another aspect, provided herein is a method for treating an inflammatory disorder or disease in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount of any of the isolated antibodies, or antigen binding fragments thereof, disclosed herein; a therapeutically effective amount of a pharmaceutical composition disclosed herein; or a therapeutically effective amount of a pharmaceutical composition comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP and a pharmaceutically acceptable excipient and a therapeutically effective amount of a pharmaceutical composition comprising an antibody, or antigen binding fragment thereof, that binds IL-13 and a pharmaceutically acceptable excipient.

[0102] In some embodiments, the mammalian subject is a human.

[0103] In some embodiments, the inflammatory disorder or disease is atopic dermatitis.AOJ-012PCAOE-0106WO

[0104] In some embodiments, the inflammatory disorder or disease is asthma.

[0105] In some embodiments, the inflammatory disorder or disease is chronic sinusitis with nasal polyps; Chronic Rhinosinusitis without Nasal Polyps (CRSsNP); eosinophilic esophagitis (EoE); an Eosinophilic gastrointestinal disorder or disease (EGID), such as Eosinophilic Gastritis (EoG), Eosinophilic Enteritis (EoN), Eosinophilic Colitis (EoC), or Eosinophilic Gastroenteritis (EGE); Churg-Strauss syndrome / Eosinophilic granulomatosis with polyangiitis (EGPA); Prurigo Nodularis (PN); Chronic Spontaneous Urticaria (CSU); Chronic Pruritis of Unknown Origin (CPUO); Bullous Pemphigoid (BP); Cold Inducible Urticaria (ColdU); Allergic Fungal Rhinosinusitis (AFRS); Allergic Bronchopulmonary Aspergillosis (AB PA); Chronic Obstructive Pulmonary Disease (COPD); an inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis; lupus; rheumatoid arthritis (RA); psoriasis; hidradenitis suppurativa; systemic sclerosis; idiopathic pulmonary fibrosis; alopecia areata; or celiac disease.

[0106] In some embodiments, the inflammatory disorder or disease is COPD.

[0107] In another aspect, provided herein is a method for treating a pathology associated with elevated levels of TSLP and / or IL- 13 in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount of any of the isolated antibodies, or antigen binding fragments thereof, disclosed herein, a pharmaceutical composition disclosed herein, or a therapeutically effective amount of a pharmaceutical composition comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP and a pharmaceutically acceptable excipient and a therapeutically effective amount of a pharmaceutical composition comprising an antibody, or antigen binding fragment thereof, that binds IL- 13 and a pharmaceutically acceptable excipient.

[0108] In another aspect, provided herein is a method of reducing biological activity of TSLP and / or IL- 13 in a mammalian subject in need thereof, the method comprising administering to the mammalian subject a therapeutically effective amount of any of the isolated antibodies, or antigen binding fragments thereof, disclosed herein, any of the pharmaceutical compositions disclosed herein, or a therapeutically effective amount of a pharmaceutical composition comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP and a pharmaceutically acceptable excipient and a therapeutically effective amount of a pharmaceutical composition comprising an antibody, or antigen binding fragment thereof, that binds IL- 13 and a pharmaceutically acceptable excipient.

[0109] In some embodiments, the mammalian subject is a human.AOJ-012PCAOE-0106WO

[0110] In some embodiments of any of the foregoing methods, the method further includes administering a hyaluronidase or a variant thereof. In some embodiments, the hyaluronidase or variant thereof is administered separately from the antibodies (e.g., in a separate composition, which may be administered before, after, or at about the same time as the antibodies). In some embodiments, the hyaluronidase or variant thereof is administered as part of a composition that contains the isolated antibody, or antigen binding fragment thereof, that binds TSLP and / or the isolated antibody, or antigen binding fragment thereof, that binds IL-13 (e.g., the hyaluronidase or variant thereof can be administered in a composition containing the anti-TSLP antibody, a composition containing the anti-IL-13 antibody, or a composition containing both of the antibodies).

[0111] In certain aspects, described herein are compositions comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL-13, and a hyaluronidase or variant thereof. In certain aspects, described herein are compositions comprising any one of the antibodies, or antigen binding fragments thereof, described herein that binds TSLP, any one of the antibodies, or antigen binding fragments thereof, described herein that binds IL-13, and any one of the hyaluronidases or variants thereof described herein.

[0112] In certain aspects, described herein are compositions comprising hyaluronidase or a variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL-13.

[0113] In certain aspects, described herein are a combination of an antibody, or antigen binding fragment thereof, that binds TSLP, an antibody, or antigen binding fragment thereof, that binds IL-13, and a hyaluronidase or variant thereof. In certain aspects, described herein are a combination of any one of the antibodies, or antigen binding fragments thereof, described herein that binds TSLP, any one of the antibodies, or antigen binding fragments thereof, described herein that binds IL-13, and a hyaluronidase or a variant thereof.

[0114] In certain aspects, described herein are combinations comprising hyaluronidase or a variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL-13.

[0115] In certain aspects, described herein are methods of treating an inflammatory disorder or disease in a human patient comprising co-administering to the patient an isolated antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL-13, and a hyaluronidase or a variant thereof. In certain aspects, described herein are methods of treating an inflammatory disorder orAOJ-012PCAOE-0106WO disease in a human patient comprising co-administering to the patient any one of the antibodies, or antigen binding fragments thereof, described herein that binds TSLP, any one of the antibodies, or antigen binding fragments thereof, described herein that binds IL- 13, and any one of the hyaluronidases or variants thereof described herein.

[0116] In certain aspects, described herein are methods of treating an inflammatory disorder or disease in a human patient comprising co-administering to the patient hyaluronidase or a variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL- 13. In certain aspects, described herein are methods of treating an inflammatory disorder or disease in a human patient comprising co-administering to the patient any one of the hyaluronidases or variants thereof described herein and any one of the multi-specific antibodies described herein (e.g., comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL- 13).

[0117] In certain embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL- 13 is a humanized, human, or chimeric antibody. In certain embodiments, the antibody, or antigen binding fragment thereof, is a monoclonal antibody. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain human constant region of a class selected from IgG, IgA, IgD, IgE, and IgM. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a human Fc region comprising a human heavy chain constant region of the class IgG and a subclass selected from IgGl, IgG2, IgG3, and IgG4. In certain embodiments, the human Fc region comprises a human IgGl Fc region.

[0118] In certain embodiments, the human Fc region of the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a human IgG sequence selected from a sequence set forth in any one of SEQ ID NOs: 47-270. In certain embodiments, the heavy chain of the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a constant heavy chain sequence set forth in SEQ ID NO: 173 or 61. In certain embodiments, the heavy chain of the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a constant heavy chain sequence set forth in SEQ ID NO: 173. In certain embodiments, the light chain of the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a constant light chain sequence set forth in SEQ ID NO: 495 or 46.AOJ-012PCAOE-0106WO

[0119] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL-13 comprises an Fc region comprising one or more amino acid substitutions, wherein the one or more amino acid substitutions result in an increase in one or more of antibody half-life, ADCC activity, ADCP activity, or CDC activity compared with the Fc region without the one or more amino acid substitutions.

[0120] In some embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises an Fc region comprising one or more amino acid substitutions, wherein the one or more amino acid substitutions result in a decrease in one or more of, ADCC activity, ADCP activity or CDC activity compared to an antibody comprising a wild-type Fc region.

[0121] In certain embodiments, the one or more amino acid substitutions is selected from the group consisting of S228P, M252Y, S254T, T256E, T256D, T250Q, H285D, T307A, T307Q, T307R, T307W, L309D, Q411H, Q311V, A378V, E380A, M428L, N434A, N434S, N297A, D265A, L234A, L235A, and N434W; optionally, wherein the one or more amino acid substitutions comprises a plurality of amino acid substitutions selected from the group consisting of M428L / N434S (LS), M252Y / S254T / T256E (YTE), T250Q / M428L, T307A / E380A / N434A, T256D / T307Q (DQ), T256D / T307W (DW), M252Y / T256D (YD), T307Q / Q311V / A378V (QVV), T256D / H285D / T307R / Q311V / A378V (DDRVV), L309D / Q311H / N434S (DHS), S228P / L235E (SPLE), L234A / L235A (LALA), M428L / N434A (LA), L235A / G237A (LAGA), L234A / L235A / G237A (LALAGA), L234A / L235A / P329G (LALAPG), D265A / YTE, LALA / YTE, LAGA / YTE, LALAGA / YTE, LALAPG / YTE, N297A / LS, D265A / LS, LALA / LS, LALAGA / LS, LALAPG / LS, N297A / DHS, D265A / DHS, LALA / DHS, LAGA / DHS, LALAGA / DHS, LALAPG / DHS, SP / YTE, SPLE / YTE, SP / LS, SPLE / LS, SP / DHS, SPLE / DHS, N297A / LA, D265A / LA, LALA / LA, LAGA / LA, LALAGA / LA, LALAPG / LA, N297A / N434A, D265A / N434A, LALA / N434A, LAGA / N434A, LALAGA / N434A, LALAPG / N434A, N297A / N434W, D265A / N434W, LALA / N434W, LAGA / N434W, LALAGA / N434W, LALAPG / N434W, N297A / DQ, D265A / DQ, LALA / DQ, LAGA / DQ, LALAGA / DQ, LALAPG / DQ, N297A / DW, D265A / DW, LALA / DW, LAGA / DW, LALAGA / DW, LALAPG / DW, N297A / YD, D265A / YD, LALA / YD, LAGA / YD, LALAGA / YD, LALAPG / YD, T307Q / Q311V / A378V (QVV), N297A / QVV, D265A / QVV, LALA / QVV, LAGA / QVV, LALAGA / QVV, LALAPG / QVV, DDRVV, N297A / DDRVV, D265A / DDRVV, LALA / DDRVV, LAGA / DDRVV, LALAGA / DDRVV, and LALAPG / DDRVV. In certainAOJ-012PCAOE-0106WO embodiments, the one or more amino acid substitutions is selected from the group consisting of LS, YTE, T250Q / M428L, T307A / E380A / N434A, DQ, DW, YD, QVV, DHS, LA, D265A / YTE, LALA / YTE, LAGA / YTE, LALAGA / YTE, LALAPG / YTE, N297A / LS, D265A / LS, LALA / LS, LALAGA / LS, LALAPG / LS, N297A / DHS, D265A / DHS, LALA / DHS, LAGA / DHS, LALAGA / DHS, LALAPG / DHS, SP / YTE, SPLE / YTE, SP / LS. SPLE / LS, SP / DHS, SPLE / DHS, N297A / LA, D265A / LA, LALA / LA, LAGA / LA, LALAGA / LA, LALAPG / LA, N297A / DQ, D265A / DQ, LALA / DQ, LAGA / DQ, LALAGA / DQ, LALAPG / DQ, N297A / DW, D265A / DW, LALA / DW, LAGA / DW, LALAGA / DW, LALAPG / DW, N297A / YD, D265A / YD, LALA / YD, LAGA / YD, LALAGA / YD, LALAPG / YD, N297A / QVV, D265A / QVV, LALA / QVV, LAGA / QVV, LALAGA / QVV, and LALAPG / QVV.

[0122] In certain embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP and / or the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a human IgGl Fc region with LALA and YTE mutations.

[0123] Although the EU numbering system is typically used to identify the positions of the various Fc mutations described herein, direct numbering can also be used. For example, in certain embodiments, an antibody described herein comprises an Fc region with YTE mutations at positions 253 / 255 / 257 or 257 / 259 / 261, respectively. In certain embodiments, an antibody described herein comprises an Fc region with LALA mutations at positions 235 / 236 or 239 / 240, respectively. In certain embodiments, an antibody described herein comprises an Fc region (e.g., an IgGl Fc region) with YTE mutations at positions 253 / 255 / 257 or 257 / 259 / 261, respectively and with LALA mutations at positions 235 / 236 or 239 / 240, respectively. In certain embodiments, the TSLP antibody described herein comprises an Fc region (e.g., an IgGl Fc region) comprising YTE mutations at positions 257 / 259 / 261, respectively and LALA mutations at positions 239 / 240, respectively. In certain embodiments, the TSLP antibody described herein comprises the VH and VL of Antibody 5 and an Fc region comprising YTE mutations at positions 257 / 259 / 261, respectively and with LALA mutations at positions 239 / 240, respectively. In certain embodiments, the IL-13 antibody described herein comprises an Fc region (e.g., an IgGl Fc region) comprising YTE mutations at positions 253 / 255 / 257, respectively and LALA mutations at positions 235 / 236, respectively. In certain embodiments, the IL- 13 antibody described herein comprises the VH and VL of Construct 133 and an Fc region comprising YTE mutations at positions 253 / 255 / 257, respectively and with LALA mutations at positions 235 / 236, respectively.AOJ-012PCAOE-0106WO

[0124] In certain embodiments the human Fc region comprises a human IgG 1 Fc region with LALA mutations. In certain embodiments the human Fc region comprises a human IgGl Fc region with YTE mutations. Tn certain embodiments the human Fc region comprises a human IgGl Fc region with LALA and YTE mutations. In certain embodiments, when direct numbering is used these “YTE” and “LALA” mutations can be located at different amino acid position numbers. For example, in one embodiment, the human Fc region comprises a human IgGl Fc region with LALA mutations at L235A / L236A and / or YTE mutations at M253Y / S255T / T257E (by direct numbering, e.g., for an IL-13 antibody described herein). In another embodiment, the human Fc region comprises a human IgGl Fc region with LALA mutations at L239A / L240A and / or YTE mutations at M257Y / S259T / T261E (by direct numbering, e.g., for a TSLP antibody described herein).

[0125] In certain embodiments, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21 ; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27. In one embodiment, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41. In one embodiment, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a heavy chain comprising a constant heavy chain sequence set forth in SEQ ID NO: 61 or 173. In one embodiment, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a light chain comprising a constant light chain sequence set forth in SEQ ID NO: 495. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH domain comprising the amino acid sequence set forth in SEQ ID NO: 34, a VL domain comprising the amino acid sequence set forth in SEQ ID NO: 41, a constant heavy chain sequence set forth in SEQ ID NO: 173 and / or a constant heavy chain sequence set forth in SEQ ID NO: 61, and a constant light chain sequence set forth in SEQ ID NO: 495. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH domain comprising the amino acid sequence set forth in SEQ ID NO: 34, a VL domain comprising the amino acid sequence set forth in SEQ ID NO: 41, a constant heavy chain sequence set forth in SEQ ID NO: 173, and a constant light chain sequence set forth in SEQ ID NO: 495. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain sequence set forth in SEQ ID NO: 499 and a light chain sequence set forth in SEQ IDAOJ-012PCAOE-0106WONO: 500. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH domain comprising the amino acid sequence set forth in SEQ ID NO: 34, a VL domain comprising the amino acid sequence set forth in SEQ ID NO: 41 , a constant heavy chain sequence set forth in SEQ ID NO: 61, and a constant light chain sequence set forth in SEQ ID NO: 495. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain sequence set forth in SEQ ID NO: 501 and a light chain sequence set forth in SEQ ID NO: 500.

[0126] In certain embodiments, the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR- L3 comprising the sequence set forth in SEQ ID NO: 285. In one embodiment, the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287. In one embodiment, the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a heavy chain comprising a constant heavy chain sequence set forth in SEQ ID NO: 61 or 173. In one embodiment, the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a light chain comprising a constant light chain sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH domain comprising the amino acid sequence set forth in SEQ ID NO: 286, a VL domain comprising the amino acid sequence set forth in SEQ ID NO: 287, a constant heavy chain sequence set forth in SEQ ID NO: 173 and / or a constant heavy chain sequence set forth in SEQ ID NO: 61, and a constant light chain sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH domain comprising the amino acid sequence set forth in SEQ ID NO: 286, a VL domain comprising the amino acid sequence set forth in SEQ ID NO: 287, a constant heavy chain sequence set forth in SEQ ID NO: 173, and a constant light chain sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain sequence set forth in SEQ ID NO: 486 and a light chain sequence set forth in SEQ ID NO: 488. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH domain comprising the amino acid sequence set forth in SEQ ID NO: 286, a VL domain comprising the amino acid sequence set forth in SEQ ID NO: 287, a constant heavy chain sequence set forth in SEQ ID NO: 61, and a constant light chain sequence set forth in SEQ IDAOJ-012PCAOE-0106WONO: 46. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain sequence set forth in SEQ ID NO: 487 and a light chain sequence set forth in SEQ ID NO: 488.

[0127] In certain embodiments, a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL- 13 is provided. In one embodiment, the antigen binding region that binds TSLP comprises a CDR- H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27. In one embodiment, the antigen binding region that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41. In another embodiment, the antigen binding region that binds IL- 13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285. In one embodiment, the antigen binding region that binds IL-13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

[0128] In certain embodiments, the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL-13 comprises a heavy chain human constant region of a class selected from IgG, IgA, IgD, IgE, and IgM. In certain embodiments, the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 comprises a human Fc region, and the human Fc region comprises a human heavy chain constant region of the class IgG and a subclass selected from IgGl, IgG2, IgG3, and IgG4. In certain embodiments, the human Fc region of the antibody that binds TSLP and / or the antibody that binds IL- 13 comprises a human IgGl Fc region. In certain embodiments, the human Fc region of the antibody that binds TSLP and / or the antibody that binds IL- 13 comprises a human IgG4 Fc region. In certain embodiments, the human Fc region of the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 comprises a human IgG2 Fc region.AOJ-012PCAOE-0106WO

[0129] In certain embodiments the human Fc region comprises a human IgG 1 Fc with LALA mutations. In certain embodiments the human Fc region comprises a human IgGl Fc region with YTE mutations. In certain embodiments the human Fc region comprises a human IgGl Fc region with LALA and YTE mutations. In certain embodiments, when direct numbering is used, these “YTE” and “LALA” mutations can be located at different amino acid position numbers. For example, in one embodiment, the human Fc region comprises a human IgGl Fc region with LALA mutations at L235A / L236A and / or YTE mutations at M253Y / S255T / T257E (e.g., in an IL-13 antibody described herein). In another embodiment, the human Fc region comprises a human IgGl Fc region with LALA mutations at L239A / L240A and / or YTE mutations at M257Y / S259T / T261E (e.g., in a TSLP antibody described herein).

[0130] In certain embodiments, the Fc region of the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 binds to Neonatal Fc receptor (FcRn). In certain embodiments, the Fc region of the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 binds an FcRn with higher affinity at pH 6.0 compared to an antibody comprising a wild-type Fc region. In certain embodiments, the Fc region of the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 binds to FcRn with a KD of <1 x 10-7 M at pH 6.0.

[0131] In certain embodiments, the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL-13 is a monoclonal antibody.

[0132] In certain embodiments, the antibody or antigen binding region that binds TSLP binds a TSLP sequence set forth in any one of the amino acid sequences of SEQ ID NOs: 271-272. In certain embodiments, the antibody or antigen binding region that binds IL-13 binds an IL- 13 sequence set forth in any one of the amino acid sequences of SEQ ID NOs: 291-294 (e.g., SEQ ID NO: 291 or SEQ ID NO: 292).

[0133] Any suitable hyaluronidase or variant thereof can be used in the compositions, combinations, and methods described herein. In certain embodiments, the hyaluronidase is a soluble hyaluronidase. In certain embodiments, the hyaluronidase is a recombinant human hyaluronidase. In certain embodiments, the recombinant human hyaluronidase comprises the amino acid sequence set forth in any one of SEQ ID NOs: 419-428 and 430-485, or a mixture thereof. In certain embodiments, the recombinant human hyaluronidase is rHuPH20 (i.e., a composition comprising one or more of SEQ ID NOs: 421-426). In certain embodiments, the rHuPH20 formulation is ENHANZE®.AOJ-012PCAOE-0106WO

[0134] In one embodiment, the recombinant human hyaluronidase includes a sequence of amino acids in any one of SEQ ID NOs: 419-428 and 430-485, or has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to a sequence of amino acids included in any one of SEQ ID NOs: 419-428 and 430-485 and retains hyaluronidase activity. In one embodiment, the recombinant human hyaluronidase comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% to the amino acid sequence of SEQ ID NO: 419. In one embodiment, the recombinant human hyaluronidase comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% to the amino acid sequence of SEQ ID NO: 421. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:419. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:419. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:420. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:420. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:421 . In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:421. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:422. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:422. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:423. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:423. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:424. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:424. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:425. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:425. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:426. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:426. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:427. In another embodiment, the recombinant human hyaluronidase consists of the amino acidAOJ-012PCAOE-0106WO sequence set forth in SEQ ID NO:427. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:428. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:428. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NQ:430. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NQ:430. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:431. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:431. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:432. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:432. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:433. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:433. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:434. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:434. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:435. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:435. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:436. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:436. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:437. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:437. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:438. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:438. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:439. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:439. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NQ:440. In another embodiment, the recombinant human hyaluronidase consists of theAOJ-012PCAOE-0106WO amino acid sequence set forth in SEQ ID NO:440. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:441. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:441. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:442. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:442. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:443. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:443. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:444. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:444. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:445. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:445. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:446. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:446. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:447. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:447. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:448. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:448. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:449. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:449. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:450. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:450. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:451. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:451. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:452. In another embodiment, the recombinant humanAOJ-012PCAOE-0106WO hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:452. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:453. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:453. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:454. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:454. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:455. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:455. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:456. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:456. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:457. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:457. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:458. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:458. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:459. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:459. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:460. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:460. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:461. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:461. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:462. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:462. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:463. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:463. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:464. In another embodiment, the recombinantAOJ-012PCAOE-0106WO human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:464. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:465. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:465. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:466. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:466. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:467. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:467. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:468. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:468. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:469. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:469. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:470. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:470. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:471. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:471. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:472. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:472. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:473. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:473. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:474. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:474. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:475. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:475. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:476. In anotherAOJ-012PCAOE-0106WO embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:476. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:477. Tn another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:477. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:478. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:478. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:479. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:479. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:480. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:480. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:481. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:481 . In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:482. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:482. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:483. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:483. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:484. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:484. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:485. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:485.

[0135] In certain embodiments, the hyaluronidase or variant thereof and antibodies (i.e., anti-IL-13 antibody, or antigen binding fragment thereof, and anti-TSLP antibody, or antigen binding fragment thereof,) or multi-specific antibody (i.e., comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL- 13) are administered in separate formulations. In certain embodiments, the hyaluronidase or variant thereof and antibodies or multi-specific antibody are administered simultaneously in separate formulations. In certain embodiments, the hyaluronidase or variant thereof is administered toAOJ-012PCAOE-0106WO the patient prior to administration of the antibodies or multi-specific antibody. In certain embodiments, the hyaluronidase or variant thereof is administered to the patient after administration of the antibodies or multi-specific antibody. Tn certain embodiments, the hyaluronidase or variant thereof is administered to the patient after administration of one of the antibodies (either the TSLP antibody or the IL- 13 antibody) but is administered before the administration of the second of the antibodies (either the TSLP antibody or the IL- 13 antibody). In certain embodiments, the hyaluronidase or variant thereof and the antibodies or multi-specific antibody are mixed and administered in a single formulation. In certain embodiments, the hyaluronidase or variant thereof and the antibodies or multi-specific antibody are administered by subcutaneous injection. In certain embodiments, the hyaluronidase or variant thereof and the antibodies or multi-specific antibody are administered by intravenous injection.

[0136] In certain embodiments, the hyaluronidase is rHuPH20 administered at a concentration of 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000, 30,000, 31,000, 32,000, 33,000, 34,000, 35,000, 36,000, 37,000, 38,000, 39,000, or 40,000 units.

[0137] In certain embodiments, methods of treating an inflammatory disorder or disease in a human patient are provided, wherein the method comprises co-administering to the patient any one of the antibodies, or antigen binding fragments thereof, that bind TSLP described herein and any one of the antibodies, or antigen binding fragments thereof, that bind IL- 13 described herein in combination with a hyaluronidase or variant thereof. In certain embodiments, methods of treating an inflammatory disorder or disease in a human patient are provided, wherein the method comprises co-administering to the patient any one of the multi -specific antibodies described herein in combination with a hyaluronidase or variant thereof. In certain embodiments, the inflammatory disorder or disease is atopic dermatitis. In certain embodiments, the treatment reduces disease severity in the patient, wherein disease severity is assessed by an atopic dermatitis disease severity outcome measure. In certain embodiments, the inflammatory disorder or disease is asthma, chronic sinusitis with nasal polyps; Chronic Rhinosinusitis without Nasal Polyps (CRSsNP); eosinophilic esophagitis (EoE); an Eosinophilic gastrointestinal disorder or disease (EGID), such as Eosinophilic Gastritis (EoG), Eosinophilic Enteritis (EoN), Eosinophilic Colitis (EoC), or Eosinophilic Gastroenteritis (EGE); Churg-Strauss syndrome / Eosinophilic granulomatosis with polyangiitis (EGPA); Prurigo Nodularis (PN); Chronic SpontaneousAOJ-012PCAOE-0106WOUrticaria (CSU); Chronic Pruritis of Unknown Origin (CPUO); Bullous Pemphigoid (BP); Cold Inducible Urticaria (ColdU); Allergic Fungal Rhinosinusitis (AFRS); Allergic Bronchopulmonary Aspergillosis (ABPA); Chronic Obstructive Pulmonary Disease (COPD); an inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis; lupus; rheumatoid arthritis (RA); psoriasis; hidradenitis suppurativa; celiac disease; idiopathic pulmonary fibrosis; alopecia areata; or systemic sclerosis.

[0138] In certain aspects, described herein are compositions comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL-13, and a hyaluronidase or variant thereof.

[0139] In certain aspects, described herein are compositions comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL- 13, and a hyaluronidase or variant thereof, wherein the antibody or antigen binding region that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27.

[0140] In certain aspects, described herein are compositions comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL- 13, and a hyaluronidase or variant thereof, wherein the antibody or antigen binding region that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41.

[0141] In certain aspects, described herein are compositions comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL- 13, and a hyaluronidase or variant thereof, wherein the antibody or antigen binding region thereof that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR- L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0142] In certain aspects, described herein are compositions comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigenAOJ-012PCAOE-0106WO binding region thereof, that binds IL-13, and a hyaluronidase or variant thereof, wherein the antibody or antigen binding region that binds IL- 13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

[0143] In certain aspects, described herein are compositions comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL-13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding fragment thereof, that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13: a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0144] In certain aspects, described herein are compositions comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL-13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41; and wherein the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

[0145] In certain aspects, described herein are compositions comprising hyaluronidase or a variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL- 13, wherein the antigen binding region that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antigen binding region that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-AOJ-012PCAOE-0106WOH3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0146] In certain aspects, described herein are compositions comprising hyaluronidase or a variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL- 13, wherein the antigen binding region that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41; and wherein the antigen binding region that binds IL-13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

[0147] In certain aspects, described herein are combinations comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL-13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding fragment thereof, that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0148] In certain aspects, described herein are combinations comprising an isolated antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL-13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 11; and wherein the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

[0149] In certain aspects, described herein are combinations comprising hyaluronidase or a variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL-13, wherein the antigenAOJ-012PCAOE-0106WO binding region that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10: a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antigen binding region that binds IL- 13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR- H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0150] In certain aspects, described herein are combinations comprising hyaluronidase or a variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL-13, wherein the antigen binding region that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41; and wherein the antigen binding region that binds IL-13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

[0151] In certain aspects, described herein are methods of treating an inflammatory disorder or disease in a human patient comprising administering to the patient an isolated antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL-13, and a hyaluronidase or a variant thereof, wherein the antibody, or antigen binding fragment thereof, that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0152] In certain aspects, described herein are methods of treating an inflammatory disorder or disease in a human patient comprising administering to the patient an isolatedAOJ-012PCAOE-0106WO antibody, or antigen binding fragment thereof, that binds TSLP, an isolated antibody, or antigen binding fragment thereof, that binds IL- 13, and a hyaluronidase or a variant thereof, wherein the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41; and wherein the antibody, or antigen binding fragment thereof, that binds IL- 13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

[0153] In certain aspects, described herein are methods of treating an inflammatory disorder or disease in a human patient comprising administering to the patient hyaluronidase or a variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL-13, wherein the antigen binding region that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antigen binding region that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR- H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

[0154] In certain aspects, described herein are methods of treating an inflammatory disorder or disease in a human patient comprising administering to the patient hyaluronidase or a variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL- 13, wherein the antigen binding region that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41; and wherein the antigen binding region that binds IL-13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

[0155] In certain embodiments of any of the foregoing aspects, the antibody, or antigen binding fragment thereof, that binds TSLP comprises a VH domain comprising the amino acid sequence set forth in SEQ ID NO: 34, a VL domain comprising the amino acid sequence set forth in SEQ ID NO: 41, a constant heavy chain sequence set forth in SEQ ID NO: 173 and / or a constant heavy chain sequence set forth in SEQ ID NO: 61, and a constant light chain sequence set forth in SEQ ID NO: 495. In certain embodiments, the antibody, orAOJ-012PCAOE-0106WO antigen binding fragment thereof, comprises a VH domain comprising the amino acid sequence set forth in SEQ ID NO: 34, a VL domain comprising the amino acid sequence set forth in SEQ ID NO: 41, a constant heavy chain sequence set forth in SEQ ID NO: 173, and a constant light chain sequence set forth in SEQ ID NO: 495. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain sequence set forth in SEQ ID NO: 499 and a light chain sequence set forth in SEQ ID NO: 500. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH domain comprising the amino acid sequence set forth in SEQ ID NO: 34, a VL domain comprising the amino acid sequence set forth in SEQ ID NO: 41, a constant heavy chain sequence set forth in SEQ ID NO: 61, and a constant light chain sequence set forth in SEQ ID NO: 495. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain sequence set forth in SEQ ID NO: 501 and a light chain sequence set forth in SEQ ID NO: 500.

[0156] In certain embodiments of any of the foregoing aspects, the antibody, or antigen binding fragment thereof, that binds IL-13 comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a constant heavy chain sequence set forth in SEQ ID NO: 173 and / or a constant heavy chain sequence set forth in SEQ ID NO: 61, and a constant light chain sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a constant heavy chain sequence set forth in SEQ ID NO: 173, and a constant light chain sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain sequence set forth in SEQ ID NO: 486 and a light chain sequence set forth in SEQ ID NO: 488. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a constant heavy chain sequence set forth in SEQ ID NO: 61, and a constant light chain sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain sequence set forth in SEQ ID NO: 487 and a light chain sequence set forth in SEQ ID NO: 488.

[0157] In certain aspects, described herein is a kit comprising: (a) a dose of an antibody, or antigen binding fragment thereof, that binds TSLP, wherein the antibody comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41; (b) a dose of an antibody, or antigen binding fragment thereof, that binds IL- 13, wherein the antibody comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forthAOJ-012PCAOE-0106WO in SEQ ID NO: 287; (c) a dose of a hyaluronidase or variant thereof; and (d) instructions for use.

[0158] In certain embodiments, the hyaluronidase is a soluble hyaluronidase. In certain embodiments, the hyaluronidase is a recombinant human hyaluronidase or variant thereof. In certain embodiments, the hyaluronidase is a recombinant human hyaluronidase. In certain embodiments, the recombinant human hyaluronidase comprises the amino acid sequence set forth in any one of SEQ ID NOs: 419-428 and 430-485, or a mixture thereof. In certain embodiments, the recombinant human hyaluronidase is rHuPH20 (i.e., a composition comprising one or more of SEQ ID NOs: 421-426). In certain embodiments, the rHuPH20 formulation is ENHANZE®.

[0159] In certain embodiments, the kit is for use in treating an inflammatory disorder or disease. In certain embodiments, the inflammatory disorder or disease is atopic dermatitis. In certain embodiments, the inflammatory disorder or disease is asthma; chronic sinusitis with nasal polyps; Chronic Rhinosinusitis without Nasal Polyps (CRSsNP); eosinophilic esophagitis (EoE); an Eosinophilic gastrointestinal disorder or disease (EGID), such as Eosinophilic Gastritis (EoG), Eosinophilic Enteritis (EoN), Eosinophilic Colitis (EoC), or Eosinophilic Gastroenteritis (EGE); Churg-Strauss syndrome / Eosinophilic granulomatosis with polyangiitis (EGPA); Prurigo Nodularis (PN); Chronic Spontaneous Urticaria (CSU); Chronic Pruritis of Unknown Origin (CPUO); Bullous Pemphigoid (BP); Cold Inducible Urticaria (ColdU); Allergic Fungal Rhinosinusitis (AFRS); Allergic Bronchopulmonary Aspergillosis (AB PA); Chronic Obstructive Pulmonary Disease (COPD); an inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis; lupus; rheumatoid arthritis (RA); psoriasis; hidradenitis suppurativa; celiac disease; idiopathic pulmonary fibrosis; alopecia areata; or systemic sclerosis.DETAILED DESCRIPTION

[0160] Described herein are compositions and combinations containing an anti-IL-13 antibody, or antigen binding fragment thereof, an anti-TSLP antibody, or antigen binding fragment thereof, and a hyaluronidase or variant thereof. The compositions and combinations can be used to treat a subject having an inflammatory disorder or disease, such as atopic dermatitis, asthma, or COPD. The antibodies, or antigen binding fragments thereof, can be administered to a subject separately from the hyaluronidase or variant thereof (e.g., in separate compositions) or may be co-formulated and administered in a single composition.AOJ-012PCAOE-0106WODefinitions

[0161] Unless otherwise defined, all terms of art, notations and other scientific terminology used herein are intended to have the meanings commonly understood by those of skill in the art. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a difference over what is generally understood in the art. The techniques and procedures described or referenced herein are generally well understood and commonly employed using conventional methodologies by those skilled in the art, such as, for example, the widely utilized molecular cloning methodologies described in Sambrook et al.. Molecular Cloning: A Laboratory Manual 4th ed. (2012) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. As appropriate, procedures involving the use of commercially available kits and reagents are generally carried out in accordance with manufacturer-defined protocols and conditions unless otherwise noted.

[0162] As used herein, the singular forms “a," “an," and “the" include plural referents unless indicated otherwise.

[0163] It is understood that aspects and embodiments of the invention described herein include “comprising,” “consisting,” and “consisting essentially of” aspects and embodiments.

[0164] For all compositions described herein, and all methods using a composition described herein, the compositions can either comprise the listed components or steps, or can “consist essentially of’ the listed components or steps. When a composition is described as “consisting essentially of” the listed components, the composition contains the components listed, and may contain other components which do not substantially affect the condition being treated, but do not contain any other components which substantially affect the condition being treated other than those components expressly listed; or, if the composition does contain extra components other than those listed which substantially affect the condition being treated, the composition does not contain a sufficient concentration or amount of the extra components to substantially affect the condition being treated. When a method is described as “consisting essentially of” the listed steps, the method contains the steps listed, and may contain other steps that do not substantially affect the condition being treated, but the method does not contain any other steps which substantially affect the condition being treated other than those steps expressly listed. As a non-limiting specific example, when a composition is described as “consisting essentially of’ a component, the composition mayAOJ-012PCAOE-0106WO additionally contain any amount of pharmaceutically acceptable carriers, vehicles, or diluents and other such components which do not substantially affect the condition being treated.

[0165] The term “vector,” as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a selfreplicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors.”

[0166] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably herein and refer to cells into which an exogenous nucleic acid has been introduced, and the progeny of such cells. Host cells include “transformants” (or “transformed cells”) and “transfectants” (or “transfected cells”), which each include the primary transformed or transfected cell and progeny derived therefrom. Such progeny may not be completely identical in nucleic acid content to a parent cell, and may contain mutations. A “recombinant host cell” or “host cell” refers to a cell that includes an exogenous polynucleotide, regardless of the method used for insertion, for example, direct uptake, transduction, f-mating, or other methods known in the art to create recombinant host cells.

[0167] As used herein, the term “eukaryote” refers to organisms belonging to the phylogenetic domain Eukarya such as animals (including but not limited to, mammals, insects, reptiles, birds, etc.), ciliates, plants (including but not limited to, monocots, dicots, algae, etc.), fungi, yeasts, flagellates, microsporidia, protists, etc.

[0168] As used herein, the term “prokaryote” refers to prokaryotic organisms. For example, a non-eukaryotic organism can belong to the Eubacteria (including but not limited to, Escherichia coli, Themius thermophilus, Bacillus stearothermophilus, Pseudomonas fluorescens. Pseudomonas aeruginosa, Pseudomonas putida, etc.) phylogenetic domain, or the Archaea (including but not limited to, Methanococcus jannaschii, Methanobacterium thermoautotrophicum, Halobacterium such as Elaloferax volcanii and Halobacterium species NRC-1, Archaeoglobus fulgidus, Pyrococcus furiosus, Pyrococcus horikoshii, Aeuropyrum pemix, etc.) phylogenetic domain.

[0169] An “effective amount” or “therapeutically effective amount” as used herein refers to an amount of therapeutic compound, such as an anti-TSLP antibody, or antigen binding fragment thereof, or an anti -IL- 13 antibody, or antigen binding fragment thereof, administered to an individual, either as a single dose or as part of a series of doses, which is effective to produce or contribute to a desired therapeutic effect, either alone or inAOJ-012PCAOE-0106WO combination with another therapeutic modality. Examples of a desired therapeutic effect are reducing an aberrant immune response, slowing or delaying disease development; stabilization of disease; and amelioration of one or more symptoms. An effective amount may be given in one or more dosages.

[0170] The term “treating” (and variations thereof such as “treat” or “treatment”) refers to clinical intervention in an attempt to alter the natural course of a disease or condition in a subject in need thereof. Treatment can be performed during the course of clinical pathology. Desirable effects of treatment include preventing recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.

[0171] The term “sufficient amount” means an amount sufficient to produce a desired effect, e.g., an amount sufficient to modulate an immune response in a subject.

[0172] As used herein, the term “subject,” “patient,” or “individual” means a mammalian subject. Exemplary subjects include humans, monkeys, dogs, cats, mice, rats, cows, horses, camels, goats, rabbits, and sheep. In certain embodiments, the subject is a human. In some embodiments the subject has a disease or condition that can be treated with an antibody, or antigen binding fragment thereof, provided herein. In some aspects, the disease or condition is atopic dermatitis. In some aspects, the disease or condition is asthma.

[0173] The term “in vitro” refers to processes that occur in a living cell growing separate from a living organism, e.g., growing in tissue culture.

[0174] The term “in vivo” refers to processes that occur in a living organism.

[0175] The term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic or diagnostic products (e.g., kits) that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic or diagnostic products.

[0176] The term “pharmaceutical composition” refers to a preparation which is in such form as to permit the biological activity of one or more active ingredient(s) contained therein to be effective in treating a subject.

[0177] As used herein, the term “pharmaceutically acceptable” refers to those compounds, materials, compositions and / or dosage forms, which are suitable for contact with the tissues of a subject, such as a mammal (e.g., a human) without excessive toxicity, irritation, allergic response and other problem complications commensurate with a reasonableAOJ-012PCAOE-0106WO benefit / risk ratio. Preferably, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in mammals, and more particularly in humans.

[0178] The terms “co-administration,” “co-administer,” and “in combination with” include the administration of two or more therapeutic agents either simultaneously, concurrently or sequentially within no specific time limits. In one embodiment, the agents are present in the cell or in the subject's body at the same time or exert their biological or therapeutic effect at the same time. In one embodiment, the therapeutic agents are in the same composition or unit dosage form. In other embodiments, the therapeutic agents are in separate compositions or unit dosage forms. In certain embodiments, a first agent can be administered prior to the administration of a second therapeutic agent.

[0179] The terms “modulate” and “modulation” refer to reducing or inhibiting or, alternatively, activating or increasing, a recited variable.

[0180] The terms “increase” and “activate” refer to an increase of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or greater in a recited variable.

[0181] The terms “reduce” and “inhibit” refer to a decrease of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%. 95%. 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or greater in a recited variable.

[0182] The term “about” indicates and encompasses an indicated value and a range above and below that value. In certain embodiments, the term “about” indicates the designated value ± 10%, ± 5%, or ± 1%. In certain embodiments, where applicable, the term “about” indicates the designated value(s) ± one standard deviation of that value(s).

[0183] The term “agonize” refers to the activation of receptor signaling to induce a biological response associated with activation of the receptor. An “agonist” is an entity that binds to and agonizes a receptor.

[0184] The term “antagonize” refers to the inhibition of receptor signaling to inhibit a biological response associated with activation of the receptor. An “antagonist” is an entity that binds to and antagonizes a receptor.

[0185] For any of the structural and functional characteristics described herein, methods of determining these characteristics are known in the art.

[0186] The term “optionally” is meant, when used sequentially, to include from one to all of the enumerated combinations and contemplates all sub-combinations.AOJ-012PCAOE-0106WO

[0187] The term “amino acid” refers to, for example, the twenty common naturally occurring amino acids. Naturally occurring amino acids include alanine (Ala; A), arginine (Arg; R), asparagine (Asn; N), aspartic acid (Asp; D), cysteine (Cys; C), glutamic acid (Glu; E), glutamine (Gin; Q), Glycine (Gly; G), histidine (His; H), isoleucine (He; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Vai; V).

[0188] The term “affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen or epitope). Unless indicated otherwise, as used herein, “affinity” refers to intrinsic binding affinity, which reflects a 1 : 1 interaction between members of a binding pair (e.g., antibody and antigen or epitope).

[0189] The term “kd” (sec-1), as used herein, refers to the dissociation rate constant of a particular antibody-antigen interaction. This value is also referred to as the koff value.

[0190] The term “ka” (M-lxsec-1), as used herein, refers to the association rate constant of a particular antibody-antigen interaction. This value is also referred to as the kon value.

[0191] The term “KD” (M), as used herein, refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. KD = kd / ka. In some embodiments, the affinity of an antibody is described in terms of the KD for an interaction between such antibody and its antigen. For clarity, as known in the art, a smaller KD value indicates a higher affinity interaction, while a larger KD value indicates a lower affinity interaction.

[0192] The term “KA” (M-l), as used herein, refers to the association equilibrium constant of a particular antibody-antigen interaction. KA = ka / kd.

[0193] As used herein, “administration” refers to providing or giving a subject a therapeutic agent (e.g., an anti-IL-13 antibody, or antigen binding fragment thereof, and / or an anti-TSLP antibody, or antigen binding fragment thereof, described herein) by any effective route. Exemplary routes of administration are described herein below.

[0194] As used herein, the term “polypeptide” describes a single polymer in which the monomers are amino acid residues which are covalently conjugated together through amide bonds. A polypeptide is intended to encompass any amino acid sequence, either naturally occurring, recombinant, or synthetically produced.

[0195] As used herein, the terms “nucleic acid” and “polynucleotide,” used interchangeably herein, refer to a polymeric form of nucleosides in any length. Typically, a polynucleotide is composed of nucleosides that are naturally found in DNA or RNA (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine,AOJ-012PCAOE-0106WO deoxyguanosine, and deoxycytidine) joined by phosphodiester bonds. The term encompasses molecules comprising nucleosides or nucleoside analogs containing chemically or biologically modified bases, modified backbones, etc., whether or not found in naturally occurring nucleic acids, and such molecules may be preferred for certain applications. Where this application refers to a polynucleotide it is understood that both DNA, RNA, and in each case both single- and double-stranded forms (and complements of each single-stranded molecule) are provided.

[0196] As used herein, the terms “conservative mutation,” “conservative substitution,” and “conservative amino acid substitution” refer to a substitution of one or more amino acids for one or more different amino acids that exhibit similar physicochemical properties, such as polarity, electrostatic charge, and steric volume. These properties are summarized for each of the twenty naturally occurring amino acids in TABLE 1 below.TABLE 1. Representative physicochemical properties of naturally occurring amino acidsAOJ-012PCAOE-0106WOFrom this table it is appreciated that the conservative amino acid families include (i) G, A, V, L and 1; (ii) D and E; (iii) C, S and T; (iv) H, K and R; (v) N and Q; and (vi) F, Y and W. A conservative mutation or substitution is therefore one that substitutes one amino acid for a member of the same amino acid family (e.g., a substitution of Ser for Thr or Lys for Arg).

[0197] The term “antibody” is used herein in its broadest sense and includes certain types of immunoglobulin molecules comprising one or more antigen-binding domains that specifically bind to an antigen or epitope. An antibody specifically includes intact antibodies (e.g., intact immunoglobulins), antibody fragments, and multi-specific antibodies.

[0198] An “anti-TSLP antibody,” “TSLP antibody,” or “TSLP specific antibody” is an antibody, as provided herein, which specifically binds to the antigen TSLP.

[0199] An “anti-IL-13 antibody,” “IL- 13 antibody,” or “IL- 13 specific antibody” is an antibody, as provided herein, which specifically binds to the antigen IL-13.

[0200] The term “epitope” means a portion of an antigen that specifically binds to an antibody.

[0201] The term “hypervariable region” or “HVR”, as used herein, refers to each of the regions of an antibody variable domain which are hypervariable in sequence and / or form structurally defined loops (“hypervariable loops”).AOJ-012PCAOE-0106WO

[0202] The term “antigen-binding domain” means the portion of an antibody that is capable of specifically binding to an antigen or epitope.

[0203] The term “chimeric antibody” refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0204] The term “human antibody” or “fully human antibody” refers to an antibody which possesses an amino acid sequence corresponding to that of an antibody produced by a human or a human cell, or derived from a non-human source that utilizes a human antibody repertoire or human antibody -encoding sequences (e.g., obtained from human sources or designed de novo). Human antibodies specifically exclude humanized antibodies.

[0205] The term “humanized antibody” refers to a protein having a sequence that differs from the sequence of an antibody derived from a non-human species by one or more amino acid substitutions, deletions, and / or additions, such that the humanized antibody is less likely to induce an immune response, and / or induces a less severe immune response, as compared to the non-human species antibody, when it is administered to a human subject.

[0206] The term “multispecific antibody” refers to an antibody that comprises two or more different antigen-binding domains that collectively specifically bind two or more different epitopes.

[0207] A “monospecific antibody” is an antibody that comprises one or more binding sites that specifically bind to a single epitope. An example of a monospecific antibody is a naturally occurring IgG molecule which, while divalent (z. e. , having two antigen-binding domains), recognizes the same epitope at each of the two antigen-binding domains. The binding specificity may be present in any suitable valency.

[0208] The term “monoclonal antibody” refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.AOJ-012PCAOE-0106WO

[0209] The term “single-chain” refers to a molecule comprising amino acid monomers linearly linked by peptide bonds. In a particular such embodiment, the C-terminus of the Fab light chain is connected to the N-terminus of the Fab heavy chain in the single-chain Fab molecule. As described in more detail herein, an scFv has a variable domain of light chain (VL) connected from its C-terminus to the N-terminal end of a variable domain of heavy chain (VH) by a polypeptide chain. Alternately the scFv comprises a polypeptide chain wherein the C-terminal end of the VH is connected to the N-terminal end of VL by a polypeptide chain.

[0210] The “Fab fragment” (also referred to as fragment antigen-binding) contains the constant domain (CL) of the light chain and the first constant domain (CHI) of the heavy chain along with the variable domains VL and VH on the light and heavy chains, respectively. The variable domains comprise the complementarity determining loops (CDR, also referred to as hypervariable region (HVR)) that are involved in antigen-binding. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region.

[0211] “F(ab’)2” fragments contain two Fab’ fragments joined, near the hinge region, by disulfide bonds. F(ab’)2 fragments may be generated, for example, by recombinant methods or by pepsin digestion of an intact antibody. The F(ab’) fragments can be dissociated, for example, by treatment with B-mercaptoethanoL

[0212] “Fv” fragments comprise a non-covalently-linked dimer of one heavy chain variable domain and one light chain variable domain.

[0213] “Single-chain Fv” or “sFv" or “scFv” includes the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. In one embodiment, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen-binding. For a review of scFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

[0214] “scFv-Fc” fragments comprise an scFv attached to an Fc domain. For example, an Fc domain may be attached to the C-terminal of the scFv. The Fc domain may follow the VH or VL, depending on the orientation of the variable domains in the scFv (z.e., VH -VL or VL - VH). Any suitable Fc domain known in the art or described herein may be used. In some cases, the Fc domain comprises an IgG4 Fc domain.AOJ-012PCAOE-0106WO

[0215] The term “single domain antibody” or “sdAb” refers to a molecule in which one variable domain of an antibody specifically binds to an antigen without the presence of the other variable domain. Single domain antibodies, and fragments thereof, are described in Arabi Ghahroudi et al., (1998) FEES Letters 414:521-526 and Muyldermans et al. (2001) Trends in Biochem. Sci. 26:230-245, each of which is incorporated by reference in its entirety. Single domain antibodies are also known as sdAbs or nanobodies. SdAbs are fairly stable and easy to express as fusion partner with the Fc chain of an antibody (Harmsen MM, De Haard HJ (2007) “Properties, production, and applications of camelid single-domain antibody fragments” Appl. Microbiol Biotechnol. 77(1): 13-22).

[0216] The terms “full length antibody,” “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a naturally occurring antibody structure and having heavy chains that comprise an Fc region. For example, when used to refer to an IgG molecule, a “full length antibody” is an antibody that comprises two heavy chains and two light chains.

[0217] The term “antibody fragment” refers to an antibody that comprises a portion of an intact antibody, such as the antigen-binding or variable region of an intact antibody. Antibody fragments include, for example, Fv fragments, Fab fragments, F(ab’)2 fragments, Fab’ fragments, scFv (sFv) fragments, and scFv-Fc fragments.

[0218] The term “Fc domain” or “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions.

[0219] The term “substantially purified” refers to a construct described herein, or variant thereof that may be substantially or essentially free of components that normally accompany or interact with the protein as found in its naturally occurring environment, i.e. a native cell, or host cell in the case of recombinantly produced antibody that in certain embodiments, is substantially free of cellular material includes preparations of protein having less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1 % (by dry weight) of contaminating protein.

[0220] The term percent “identity,” in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that have a specified percentage of nucleotides or amino acid residues that are the same, when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described below (e.g., using publicly available computer software such asAOJ-012PCAOE-0106WOBLAST, BLASTP, BLASTN, BLAST-2, ALIGN, MEGALIGN (DNASTAR), CLUSTALW, CLUSTAL OMEGA, or MUSCLE software or other algorithms available to persons of skill) or by visual inspection. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (ncbi.nlm.nih.gov). Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Depending on the application, the percent “identity” can exist over a region of the sequence being compared, e.g., over a functional domain, or, alternatively, exist over the full length of the two sequences to be compared.

[0221] For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

[0222] Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman & Wunsch, (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson & Lipman, (1988) Proc. Nat’l. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Ausubel et al., supra).

[0223] One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al. (1990) J. Mol. Biol. 215:403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov / ).

[0224] Ranges recited herein are understood to be shorthand for all of the values within the range, inclusive of the recited endpoints. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43. 44, 45, 46, 47, 48, 49, and 50.AOJ-012PCAOE-0106WO

[0225] It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise.

[0226] The term "atopic dermatitis disease severity outcome measure" refers to a determination of certain signs, symptoms, features or parameters that have been associated with atopic dermatitis and that can be quantitatively or qualitatively assessed. Exemplary atopic dermatitis disease severity outcome measures include "Eczema Area and Severity Index" (EASI), "Severity Scoring of Atopic Dermatitis" (SCORAD), "Validated Investigator Global Assessment-Atopic Dermatitis" (vIGA-AD), "Investigator Global Assessment of Signs" (IGSA), Rajka / Langeland Atopic Dermatitis Severity Score, “Body Surface Area” (BSA), and patient-reported outcomes including Pruritus Visual Analog Scale (an aspect of disease severity assessed as part of SCORAD), Sleep Loss Visual Analog Scale (an aspect of disease severity assessed as part of SCORAD), Atopic Dermatitis Symptom Diary (ADSD), Atopic Dermatitis Impact Questionnaire (ADIQ), Dermatology Life Quality Index (DLQI) (Finlay and Khan, Clin Exper Dermatol 1994:19:210), 5-D Itch Scale (Elman et al., Br J Dermatol 2010; 162(3): 587-593), Itch Numeric Rating Scale (I-NRS) (see Naegeli et al., International Journal of Dermatology. 2015;54(6):715-722; and Newton L, et al., I. Patient Rep. Outcomes. 2019;3( 1 ):42), and the Patient-Oriented Eczema Measure (POEM) (www.nottingham.ac.uk / research / groups / cebd / resources / poem.aspx).Hyaluronidases

[0227] As used herein, “hyaluronidase” refers to an enzyme that degrades hyaluronic acid, which constitutes an essential part of the extracellular matrix. Included in this definition are naturally occurring hyaluronidases, recombinant hyaluronidases, both human and from other sources, as well as variants thereof. Such hyaluronidases include, but are not limited to, nonhuman hyaluronidases, including bacterial hyaluronidases, bovine hyaluronidases, ovine hyaluronidases, and variants thereof. Reference to hyaluronidase refers to all forms, including variants.

[0228] Hyaluronidases were initially discovered in bacteria, and are now known to be widely distributed in nature and have been found in many different species, including insects, snakes, and mammals. Human hyaluronidase is present both in organs (e.g., testis, spleen, skin, eyes, liver, kidneys, uterus, and placenta) and in body fluids e.g., tears, blood, and semen). In the human, six different hyaluronidases, HYAL1-4, HYAL-P1 and PH-20, have been identified. PH-20 exerts the strongest biologic activity, is found in high concentrationsAOJ-012PCAOE-0106WO in the testicles, and can be localized on the head and the acrosome of human spermatozoa (see, e.g., Weber GC, et al., Adv. Exp. Med. Biol. 2019; 1148:255-277).

[0229] Hyaluronidases are classified into three categories according to their mechanism of action (see, e.g., Jung H., Arch. Plast. Surg. 2020 Jul;47(4):297-300). First, mammalian hyaluronidases are endo-P-N-acetylhexosaminidases that break down P-1,4 glycosidic linkages to form tetrasaccharides. Second, leech / hookworm hyaluronidases are endo-P-D- glucuronidases that break down P-1,3 glycosidic bonds to form pentasaccharides and hexasaccharides. Finally, microbial hyaluronidases are classified as hyaluronate lyases. Unlike other hyaluronidases, they do not catalyze hydrolysis reactions. Instead, they produce unsaturated disaccharides through a P-elimination reaction at P-1,4 glycosidic linkage.

[0230] Hyaluronidases can also be classified into two types according to the pH at which they are most active (see, e.g., Jung H., Arch. Plast. Surg. 2020 Jul;47(4):297-300). Acidactive hyaluronidases are activated at a pH of 3 to 4. Neutral-active hyaluronidases, which include the hyaluronidase enzymes found in snake and bee venom, are activated at a pH of 5 to 8 (see, e.g., Cavallini M, et al., Aesthet. Surg. J. 2013;33: 1167-74).

[0231] Hyaluronidase use has become more diverse and widespread in clinical practice. Today, animal-derived bovine or ovine testicular hyaluronidases, as well as synthetic hyaluronidases, are clinically applied as adjuncts to increase the bioavailability of drugs, for the therapy of extravasations, or for the management of complications associated with the aesthetic injection of hyaluronic acid-based fillers.

[0232] Exemplary of hyaluronan degrading enzymes are hyaluronidases, and particular chondroitinases and lyases that have the ability to depolymerize hyaluronan. Exemplary chondroitinases that are hyaluronan degrading enzymes include, but are not limited to, chondroitin ABC lyase (also known as chondroitinase ABC), chondroitin AC lyase (also known as chondroitin sulfate lyase or chondroitin sulfate eliminase) and chondroitin C lyase. Chondroitin ABC lyase comprises two enzymes, chondroitin-sulfate-ABC endolyase (EC 4.2.2.20) and chondroitin-sulfate-ABC exolyase (EC 4.2.2.21). Exemplary chondroitin- sulfate-ABC endolyases and chondroitin-sulfate-ABC exolyases include, but are not limited to, those from Proteus vulgaris and Flavobacterium heparinum (the Proteus vulgaris chondroitin-sulfate-ABC endolyase (e.g., see Sato et al. (1994) Appl. Microbiol. Biotechnol. 41 (1 ): 39-46)). Exemplary chondroitinase AC enzymes from the bacteria include, but are not limited to, those from Flavobacterium heparinum, Victivallis vadensis, and Arthrobacter aurescens (see, e.g., Tkalec et al. (2000) Applied and Environmental Microbiology 66(1):29- 35; Ernst et al. (1995) Critical Reviews in Biochemistry and Molecular Biology 30(5):387-AOJ-012PCAOE-0106WO444). Exemplary chondroitinase C enzymes from the bacteria include, but are not limited to, those from Streptococcus and Flavobacterium (Hibi et al. (1989) FEMS-Microbiol-Lett. 48(2): 121 -4; Michelacci et al. (1976) J. Biol. Chem. 251 :1 154-8; Tsuda et al. (1999) Eur. J. Biochem. 262:127-133).

[0233] Hyaluronidases include bacterial hyaluronidases (EC 4.2.2.1 or EC 4.2.99.1), hyaluronidases from leeches, other parasites, and crustaceans (EC 3.2. 1.36), and mammaliantype hyaluronidases (EC 3.2.1 .35). Hyaluronidases include any of non-human origin including, but not limited to, murine, canine, feline, leporine, avian, bovine, ovine, porcine, equine, piscine, ranine, bacterial, and any from leeches, other parasites, and crustaceans.Exemplary non-human hyaluronidases include hyaluronidases from cows (SEQ ID NOs:10, 11, 64 of US Patent No.: 8,568,713) and BH55 (U.S. Pat. Nos. 5,747,027 and 5,827.721), yellow jacket wasp (SEQ ID NOs:12 and 13 of US Patent No.: 8,568,713), honey bee (SEQ ID NO:14 of US Patent No.: 8,568,713), white -face hornet (SEQ ID NO:15 of US Patent No.:8,568,713), paper wasp (SEQ ID NO: 16 of US Patent No.: 8,568,713), mouse (SEQ ID NOs: 17-19, and 32 of US Patent No.: 8.568,713), pig (SEQ ID NOs:20-21of US Patent No.:8,568,713), rat (SEQ ID NOs:22-24, and 31 of US Patent No.: 8,568,713), rabbit (SEQ ID NO:25 of US Patent No.: 8,568,713), sheep (SEQ ID NOs:26, 27, 63 and 65 of US Patent No.: 8,568,713), orangutan (SEQ ID NO:28 of US Patent No.: 8,568,713), cynomolgus monkey (SEQ ID NO:29 of US Patent No.: 8,568,713), guinea pig (SEQ ID NO:30 of US Patent No.: 8,568,713), Arthrobacter sp. (strain FB24) (SEQ ID NO:67 of US Patent No.:8.568.713), Bdellovibrio bacteriovorus (SEQ ID NO:68 of US Patent No.: 8,568,713), Propionibacterium acnes (SEQ ID NO:69 of US Patent No.: 8,568,713), Streptococcus agalactiae ((SEQ ID NO:70 of US Patent No.: 8,568,713); 18RS21 (SEQ ID NO:71 of US Patent No.: 8,568,713 ); serotype la (SEQ ID NO:72 of US Patent No.: 8,568,713); serotype III (SEQ ID NO:73 of US Patent No.: 8,568,713), Staphylococcus aureus (strain COL) (SEQ ID NO:74 of US Patent No.: 8,568,713 ); strain MRSA252 (SEQ ID NOs:75 and 76 of US Patent No.: 8,568,713 of US Patent No.: 8,568,713); strain MSSA476 (SEQ ID NO:77 of US Patent No.: 8,568,713); strain NCTC 8325 (SEQ ID NO:78 of US Patent No.: 8,568,713 ); strain bovine RF122 (SEQ ID NOs:79 and 80 of US Patent No.: 8,568,713); strain USA300 (SEQ ID NO:81 of US Patent No.: 8,568,713), Streptococcus pneumoniae (SEQ ID NO:82 of US Patent No.: 8,568,713); strain ATCC BAA-255 / R6 (SEQ ID NO:83 of US Patent No.:8.568.713): serotype 2, strain D39 / NCTC 7466 (SEQ ID NO:84 of US Patent No.:8.568.713), Streptococcus pyogenes (serotype (SEQ ID NO:85 of US Patent No.: 8,568,713); serotype M2, strain MGAS10270 (SEQ ID NO:86 of US Patent No.: 8,568,713); serotypeAOJ-012PCAOE-0106WOM4, strain MGAS10750 (SEQ ID NO:87 of US Patent No.: 8,568,713); serotype M6 (SEQ ID NO:88 of US Patent No.: 8,568,713); serotype M12, strain MGAS2096 (SEQ ID NOs:89 and 90 of US Patent No.: 8,568,713); serotype Ml 2, strain MGAS9429 (SEQ ID NO:91 of US Patent No.: 8,568,713); serotype M28 (SEQ ID NO:92 of US Patent No.: 8,568,713); Streptococcus suis (SEQ ID NOs:93-95 of US Patent No.: 8,568,713 ); Vibrio fischeri (strain ATCC 700601 / ES 114 (SEQ ID NO:96 of US Patent No.: 8,568,713), and the Streptomyces hyaluronolyticus hyaluronidase enzyme, which is specific for hyaluronic acid and does not cleave chondroitin or chondroitin sulfate (Ohya, T. and Kaneko, Y. (1970) Biochim. Biophys. Acta 198:607). Hyaluronidases also include those of human origin. Exemplary human hyaluronidases include PH20 (SEQ ID NO: 1 of US Patent No. 8,568,713), HYAL1 (SEQ ID NO:36 of US Patent No.: 8,568.713), HYAL2 (SEQ ID NO:37 of US Patent No.: 8,568.713), HYAL3 (SEQ ID NO:38 of US Patent No.: 8,568,713), and HYAL4 (SEQ ID NO:36 of US Patent No.: 8,568,713). The sequences and contents of US Patent No. 8,568,713 are expressly incorporated herein by reference. Also included amongst hyaluronidases are soluble hyaluronidases, including, ovine and bovine PH20, soluble human PH20 and soluble rHuPH20. Examples of commercially available bovine or ovine soluble hyaluronidases include Vitrase® (ovine hyaluronidase) and Amphadase ® (bovine hyaluronidase).

[0234] Hyaluronidases as described herein include precursor hyaluronan degrading enzyme polypeptides and mature hyaluronan degrading enzyme polypeptides (such as those in which a signal sequence has been removed), truncated forms thereof that have activity, and includes allelic variants and species variants, variants encoded by splice variants, and other variants, including polypeptides that have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the polypeptides set forth in SEQ ID NOs: 419-428 and 430-485. Hyaluronidases also include those that contain chemical or posttranslational modifications and those that do not contain chemical or posttranslational modifications. Such modifications include, but are not limited to, pegylation, albumination, glycosylation, farnesylation. carboxylation, hydroxylation, phosphorylation, and other polypeptide modifications known in the art.

[0235] As used herein, a soluble hyaluronidase refers to a polypeptide characterized by its solubility under physiologic conditions. Soluble hyaluronidases can be distinguished, for example, by its partitioning into the aqueous phase of a Triton X-l 14 solution warmed to 37 °C (Bordier et al., (1981) J. Biol. Chem., 256: 1604-7). Membrane-anchored, such as lipid anchored hyaluronidases, will partition into the detergent rich phase, but will partition into the detergent -poor or aqueous phase following treatment with Phospholipase-C. IncludedAOJ-012PCAOE-0106WO among soluble hyaluronidases are membrane anchored hyaluronidases in which one or more regions associated with anchoring of the hyaluronidase to the membrane has been removed or modified, where the soluble form retains hyaluronidase activity. Soluble hyaluronidases include recombinant soluble hyaluronidases and those contained in or purified from natural sources.

[0236] As used herein, activity refers to a functional activity or activities of a polypeptide or portion thereof associated with a full-length (complete) protein. Functional activities include, but are not limited to, biological activity, catalytic or enzymatic activity, antigenicity (ability to bind or compete with a polypeptide for binding to an anti-polypeptide antibody), immunogenicity, ability to form multimers, and the ability to specifically bind to a receptor or ligand for the polypeptide.

[0237] As used herein, hyaluronidase activity refers to the ability to enzymatically catalyze the cleavage of hyaluronic acid. The United States Pharmacopeia (USP) XXII assay for hyaluronidase determines hyaluronidase activity indirectly by measuring the amount of higher molecular weight hyaluronic acid, or hyaluronan, (HA) substrate remaining after the enzyme is allowed to react with the HA for 30 min at 37 °C (USP XXII-NF XVII (1990) 644- 645 United States Pharmacopeia Convention, Inc, Rockville, Md.). A Reference Standard solution can be used in an assay to ascertain the relative activity, in units, of any hyaluronidase. In vitro assays to determine the hyaluronidase activity of hyaluronidases, such as soluble rHuPH20, are known in the art. Exemplary assays include the microturbidity assay described below (see, e.g., Example 3 of US Patent No. :8, 568, 713) that measures cleavage of hyaluronic acid by hyaluronidase indirectly by detecting the insoluble precipitate formed when the uncleaved hyaluronic acid binds with serum albumin. Reference Standards can be used, for example, to generate a standard curve to determine the activity in Units of the hyaluronidase being tested.

[0238] As used herein, "functionally equivalent amount" or grammatical variations thereof, with reference to a hyaluronan degrading enzyme, refers to the amount of hyaluronan degrading enzyme that achieves the same effect as an amount (such as a known number of Units of hyaluronidase activity) of a reference enzyme, such as a hyaluronidase. For example, the activity of any hyaluronan degrading enzyme can be compared to the activity of rHuPH20 to determine the functionally equivalent amount of a hyaluronan degrading enzyme that would achieve the same effect as a known amount of rHuPH20. For example, the ability of a hyaluronan degrading enzyme to act as a spreading or diffusing agent can be assessed by injecting it into the lateral skin of mice with trypan blue (see, e.g. U.S. Pat. Publication No.AOJ-012PCAOE-0106WO20050260186), and the amount of hyaluronan degrading enzyme required to achieve the same amount of diffusion as, for example, 100 units of a Hyaluronidase Reference Standard, can be determined. The amount of hyaluronan degrading enzyme required is, therefore, functionally equivalent to 100 units.

[0239] Exemplary hyaluronan degrading enzymes are hyaluronidases, particularly soluble hyaluronidases, such as a PH20, or a truncated or variant form thereof. The PH20 can be, for example, an ovine, bovine or truncated human PH20. The human PH20 mRNA transcript is normally translated to generate a 509 amino acid precursor polypeptide (SEQ ID NO:419; and replicated below) containing a 35 amino acid signal sequence at the N-terminus (amino acid residue positions 1-35) and a 19 amino acid glycosylphosphatidylinositol (GPI) anchor attachment signal sequence at the C-terminus (amino acid residue positions 491-509). The mature PH20 is, therefore, a 474 amino acid polypeptide set forth in SEQ ID NO:420. Following transport of the precursor polypeptide to the ER and removal of the signal peptide, the C-tenninal GPI-attachment signal peptide is cleaved to facilitate covalent attachment of a GPI anchor to the newly-formed C-terminal amino acid at the amino acid position corresponding to position 490 of the precursor polypeptide set forth in SEQ ID NO:419. Thus, a 474 amino acid GPI-anchored mature polypeptide with an amino acid sequence set forth in SEQ ID NO:420 is produced.

[0240] The amino acid sequence of the human PH20 precursor polypeptide (SEQ ID NO:419; 509 amino acids) is as follows:MGVLKFKHIFFRSFVKSSGVSQIVFTFLLIPCCLTLNFRAPPVIPNVPFLWAWNAPSEF CLGKFDEPLDMSLFSFIGSPRINATGQGVTIFYVDRLGYYPYIDSITGVTVNGGIPQKIS LQDHLDKAKKDITFYMPVDNLGMAVIDWEEWRPTWARNWKPKDVYKNRSIELVQ QQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGKLLRPNHLWGYYLFPDCYNHHY KKPGYNGSCFNVEIKRNDDLSWLWNESTALYPSIYLNTQQSPVAATLYVRNRVREAI RVSKIPDAKSPLPVFAYTRIVFTDQVLKFLSQDELVYTFGETVALGASGIVIWGTLSIM RSMKSCLLLDNYMETILNPYIINVTLAAKMCSQVLCQEQGVCIRKNWNSSDYLHLNP DNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCSCYSTLSCKEKADVKDTDAVDVCI ADGVCIDAFLKPPMETEEPQIFYNASPSTLSATMFIVSILFLIISSVASL.

[0241] The amino acid sequence of the mature PH20 polypeptide (SEQ ID NO: 420; 474 amino acids) is as follows:LNFRAPPVIPNVPFLWAWNAPSEFCLGKFDEPLDMSLFSFIGSPRINATGQGVTIFYVD RLGYYPYIDSITGVTVNGGIPQKISLQDHLDKAKKDITFYMPVDNLGMAVIDWEEWR PTWARNWKPKDVYKNRSIELVQQQNVQLSLTEATEKAKQEFEKAGKDFLVETIKLGAOJ-012PCAOE-0106WOKLLRPNHLWGYYLFPDCYNHHYKKPGYNGSCFNVEIKRNDDLSWLWNESTALYPSI YLNTQQSPVAATLYVRNRVREAIRVSKIPDAKSPLPVFAYTRIVFTDQVLKFLSQDEL VYTFGETVALGASGTVIWGTLSIMRSMKSCLLLDNYMETILNPYIINVTLAAKMCSQV LCQEQGVCIRKNWNSSDYLHLNPDNFAIQLEKGGKFTVRGKPTLEDLEQFSEKFYCS CYSTLSCKEKADVKDTDAVDVCIADGVCIDAFLKPPMETEEPQIFYNASPSTLSATMF IVSILFLIISSVASL.

[0242] Human PH20 exhibits hyaluronidase activity at both neutral and acid pH. In one aspect, human PH20 is the prototypical neutral-active hyaluronidase that is generally locked to the plasma membrane via a GPI anchor. In another aspect, PH20 is expressed on the inner acrosomal membrane where it has hyaluronidase activity at both neutral and acid pH. It appears that PH20 contains two catalytic sites at distinct regions of the polypeptide: the Peptide 1 and Peptide 3 regions (Cherr et al., (2001) Matrix Biology 20:515-525). Evidence suggests that the Peptide 1 region of PH20, which corresponds to amino acid positions 107- 137 of the mature polypeptide set forth in SEQ ID NO:420 and positions 142-172 of the precursor polypeptide set forth in SEQ ID NO:419, is required for enzyme activity at neutral pH. Amino acids at positions 111 and 113 (corresponding to the mature PH20 polypeptide set forth in SEQ ID NO:420) within this region appear to be important for activity, as mutagenesis by amino acid replacement results in PH20 polypeptides with 3% hyaluronidase activity or undetectable hyaluronidase activity, respectively, compared to the wild-type PH20 (Arming et al., (1997) Eur. J. Biochem. 247:810-814).

[0243] The Peptide 3 region, which corresponds to amino acid positions 242-262 of the mature polypeptide set forth in SEQ ID NO:420, and positions 277-297 of the precursor polypeptide set forth in SEQ ID NO:419, appears to be important for enzyme activity at acidic pH. Within this region, amino acids at positions 249 and 252 of the mature PH20 polypeptide appear to be essential for activity, and mutagenesis of either one results in a polypeptide essentially devoid of activity (Arming et al., (1997) Eur. J. Biochem. 247:810- 814).

[0244] In addition to the catalytic sites, PH20 also contains a hyaluronan-binding site. Experimental evidence suggests that this site is located in the Peptide 2 region, which corresponds to amino acid positions 205-235 of the precursor polypeptide set forth in SEQ ID NO: 419 and positions 170-200 of the mature polypeptide set forth in SEQ ID NO:420. This region is highly conserved among hyaluronidases and is similar to the heparin binding motif. Mutation of the arginine residue at position 176 (corresponding to the mature PH20 polypeptide set forth in SEQ ID NO:420) to a glycine results in a polypeptide with only aboutAOJ-012PCAOE-0106WO1% of the hyaluronidase activity of the wild type polypeptide (Arming et al., (1997) Eur. J. Biochem. 247:810-814).

[0245] There are seven potential N-linked glycosylation sites in human PH20 at N82, N166, N235, N254, N368, N393, N490 of the polypeptide exemplified in SEQ ID NO:419. Because amino acids 36 to 464 of SEQ ID NO:419 appear to contain the minimally active human PH20 hyaluronidase domain, the N-linked glycosylation site N-490 is not required for proper hyaluronidase activity. There are six disulfide bonds in human PH20. Two disulfide bonds between the cysteine residues C60 and C351 and between C224 and C238 of the polypeptide exemplified in SEQ ID NO:419 (corresponding to residues C25 and C316, and C189 and C203 of the mature polypeptide set forth in SEQ ID NO:420, respectively). A further four disulfide bonds are formed between the cysteine residues C376 and C387: between C381 and C435; between C437 and C443; and between C458 and C464 of the polypeptide exemplified in SEQ ID NO: 419 (corresponding to residues C341 and C352; between C346 and C400; between C402 and C408; and between C423 and C429 of the mature polypeptide set forth in SEQ ID NO:420, respectively).

[0246] As used herein, soluble recombinant human PH20 (rHuPH20) refers to a soluble form of human PH20 that is recombinantly expressed in Chinese Hamster Ovary (CHO) cells. Soluble human PH20 or sHuPH20 includes mature polypeptides lacking all or a portion of the glycosylphospatidylinositol (GPI) attachment site at the C-terminus such that upon expression, the polypeptides are soluble.

[0247] Soluble rHuPH20 is encoded by a nucleic acid that includes the signal sequence and is set forth in SEQ ID NO:429. Also included are DNA molecules that are allelic variants thereof and other soluble variants. The nucleic acid encoding soluble rHuPH20 is expressed in CHO cells which secrete the mature polypeptide.

[0248] SEQ ID NO: 429 encodes amino acids 1-482 of the human PH20 precursor polypeptide (amino acids 1-482 of SEQ ID NO: 419). Post translational processing removes the 35 amino acid signal sequence, leaving a 447 amino acid soluble recombinant human PH20 (SEQ ID NO: 421). As produced in the culture medium, there is heterogeneity at the C- terminus such that the product, designated rHuPH20, includes a mixture of species that can include any one or more of SEQ ID NOs: 421-426 in various abundance. Typically, rHuPH20 is produced in cells that facilitate correct N-glycosylation to retain activity, such as CHO cells (e.g., DG44 CHO cells). rHuPH20 may be produced by expressing a polynucleotide encoding amino acids 36-482 of SEQ ID NO: 419 in a cell, such as a CHO cell, and the polynucleotide encoding amino acids 36-482 of SEQ ID NO: 419 may be linked to the nativeAOJ-012PCAOE-0106WO signal sequence (amino acids 1-35 of SEQ ID NO: 419, as in SEQ ID NO: 429) or a heterologous signal sequence. The production of rHuPH20 is described in U.S. Patent No. 8,568,713 and U.S. Patent No. 8,343,487, each of which is incorporated herein by reference.

[0249] Exemplary sHuPH20 polypeptides include mature polypeptides having an amino acid sequence set forth in any one of SEQ ID NOs: 421-428 and 430-485. Other variants can have 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to any one of SEQ ID NOs: 421-428 and 430-485, as long they retain a hyaluronidase activity and are soluble. Corresponding allelic variants and other variants also are included, including those corresponding to the precursor human PH20 polypeptide set forth in SEQ ID NO:419 and the mature human PH20 polypeptide set forth in SEQ ID NO: 420.

[0250] rHuPH20 was approved by the US Food and Drug Administration in 2005 as an adjuvant to increase the dispersion and absorption of other injected drugs. Recombinant human hyaluronidase PH20 is a transiently and locally-acting permeation enhancer that increases the dispersion and absorption of other injected agents. Recombinant human hyaluronidase PH20 depolymerizes hyaluronic acid (HA) at the injection site causing rapid decrease in the viscosity of the extracellular matrix, allowing bulk fluid flow and facilitating dispersion and absorption of coadministered agents (rHuPH20 Investigator’s Brochure, 2018).

[0251] rHuPH20 is a glycosylated single chain protein with up to 447 amino acids, synthesized in CHO cells. As described above, rHuPH20 may be produced from a polynucleotide encoding amino acids 1-482 of SEQ ID NO: 419 (set forth in SEQ ID NO: 429), and post translational processing removes the 35 amino acid signal sequence, resulting in a polypeptide containing amino acids 36-482 of SEQ ID NO: 419 (set forth in SEQ ID NO: 421). As produced in the culture medium there is heterogeneity at the C-terminus such that the resulting rHuPH20 includes a mixture of species that can include any one or more of SEQ ID NOs: 421-426 in various abundance. Recombinant human hyaluronidase PH20 degrades HA under physiologic conditions and acts as a spreading factor in vivo. Therefore, when combined (co-mixed) or co-formulated with certain injectable drugs, rHUPH20 facilitates the absorption and dispersion of these drugs by temporarily reducing resistance to bulk fluid flow in the subcutaneous space. The permeability barrier in these tissues is restored to pre-injection levels within 24 to 48 hours after injection of rHuPH20.

[0252] Any suitable hyaluronidase (e.g., a recombinant human hyaluronidase) can be used in the methods, compositions, and combinations described herein, including, but notAOJ-012PCAOE-0106WO limited to, those described in US Patent No.: 7,767,429 (e.g., SEQ ID NO: 1), US Patent No.: 7,846,431 (e.g., SEQ ID NO: 1), US Patent No.: 7,871,607 (e.g., SEQ ID NO: 1), US Patent No.: 8,105,586 (e.g., SEQ ID NO: 1), US Patent No.: 8,202,517 (e.g., SEQ ID NO: 1), US Patent No.: 8,257,699 (e.g., SEQ ID NO:1), US Patent No.: 8,450,470 (e.g., SEQ ID NO: 1), US Patent No.: 8,431,124 (e.g., SEQ ID NO:1),US Patent No.: 8,431,380 (e.g., SEQ ID NO: 1), US Patent No.: 8,580,252 (e.g., SEQ ID NO:1), US Patent No.: US 8,765,685 (e.g., SEQ ID NO: 1), US Patent No.: US 8,772,246 (e.g., SEQ ID NO:1),US Patent No.: US 9,211,315 (e.g., SEQ ID NO:1), US Patent No.: US 9,562,223 (e.g., SEQ ID NO:1), US Patent No.: US 9,677,061 (e.g., SEQ ID NO:1), US Patent No.: US 9,677,062 (e.g., SEQ ID NO:1), US Patent No.: US 5,721,348 (e.g., SEQ ID NO:6), US 20210155913, US 20210363270, and US 20220289864, the contents of each of which are expressly incorporated herein by reference. The generation of such recombinant human hyaluronidases is described in U.S. Patent No.: 7,767,429; U.S. Patent No.: 7,871,607; and US20060104968, the contents of each of which are expressly incorporated herein by reference.

[0253] An exemplary recombinant human hyaluronidase is a soluble hyaluronidase provided as a composition designated rHuPH20, i.e.. the active ingredient in the commercial product Hylenex® recombinant (hyaluronidase human injection), which is supplied as ENHANZE® drug product. ENHANZE® is a formulation containing rHuPH20 that can be admixed with an antibody prior to subcutaneous injection.

[0254] Hyaluronidases that have altered properties, such as increased stability and / or activity, have been produced and can also be used, including, but not limited to those described in U.S. Pat. No. 9,447,401, U.S. Pat. No. 10,865,400, and U.S. Pat. No.11,041,149, the contents of each of which are expressly incorporated herein by reference. These patents provide about 7000 examples in which the effects of replacing each amino acid with 15 other amino acids on activity and stability were identified and described.

[0255] Other variants are known to those of skill in the art including those described, for example, in WQ2020 / 022791 and WQ2020197230A, the contents of each of which are expressly incorporated herein by reference. These variant polypeptides include replacements, insertions, and deletions, including one or more amino acid residues S343E, M345T, K349E, L353A, L354I, N356E, and 136 IT. Variants that contain such modifications and others are set forth in SEQ ID NOs: 60-115 from WQ2020 / 022791. W02021 / 150079 also provides variant polypeptides described as having increased stability.

[0256] In one embodiment, the recombinant human hyaluronidase includes a sequence of amino acids in any one of SEQ ID NOs: 419-428 and 430-485, or has at least 80%, 81 %,AOJ-012PCAOE-0106WO82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%. 96%, 97%, 98%, or 99% sequence identity to a sequence of amino acids included in any one of SEQ ID NOs: 419-428 and 430-485 and retains hyaluronidase activity. In one embodiment, the recombinant human hyaluronidase comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% to the amino acid sequence of SEQ ID NO: 419. In one embodiment, the recombinant human hyaluronidase comprises a sequence having at least 95%, 96%, 97%, 98%, or 99% to the amino acid sequence of SEQ ID NO: 421. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:419. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:419. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:420. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:420. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:421. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:421. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:422. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:422. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:423. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:423. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:424. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:424. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:425. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:425. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:426. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:426. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:427. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:427. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:428. In anotherAOJ-012PCAOE-0106WO embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:428. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:430. Tn another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:430. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:431. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:431. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:432. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:432. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:433. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:433. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:434. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:434. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:435. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:435. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:436. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:436. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:437. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:437. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:438. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:438. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:439. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:439. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:440. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:440. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:441. InAOJ-012PCAOE-0106WO another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:441. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:442. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:442. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:443. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:443. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:444. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:444. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:445. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:445. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:446. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:446. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:447. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:447. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:448. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:448. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:449. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:449. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:450. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:450. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:451 . In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:451. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:452. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:452. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence setAOJ-012PCAOE-0106WO forth in SEQ ID NO:453. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:453. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:454. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:454. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:455. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:455. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:456. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:456. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:457. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:457. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:458. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:458. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:459. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:459. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:460. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NQ:460. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:461. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:461. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:462. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:462. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:463. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:463. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:464. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:464. In another embodiment, the recombinant human hyaluronidase comprises the amino acidAOJ-012PCAOE-0106WO sequence set forth in SEQ ID NO:465. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:465. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:466. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:466. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:467. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:467. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:468. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:468. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:469. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:469. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NQ:470. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NQ:470. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:471. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:471. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:472. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:472. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:473. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:473. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:474. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:474. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:475. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:475. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:476. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:476. In another embodiment, the recombinant human hyaluronidaseAOJ-012PCAOE-0106WO comprises the amino acid sequence set forth in SEQ ID NO:477. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:477. Tn another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:478. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:478. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:479. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:479. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NQ:480. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NQ:480. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:481. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:481. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:482. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:482. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:483. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:483. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:484. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:484. In another embodiment, the recombinant human hyaluronidase comprises the amino acid sequence set forth in SEQ ID NO:485. In another embodiment, the recombinant human hyaluronidase consists of the amino acid sequence set forth in SEQ ID NO:485.Anti-TSLP and Anti-IL-13 AntibodiesAntibody Structure

[0257] The present application provides antibodies, or antigen binding fragments thereof, and compositions comprising an antibody, or antigen binding fragment thereof, which binds TSLP and an antibody, or antigen binding fragment thereof, which binds interleukin (IL)-13. In certain embodiments, the TSLP and / or IL- 13 antibody, or antigen binding fragment thereof, is an antibody comprising a modified Fc region.AOJ-012PCAOE-0106WO

[0258] The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. There are four subtypes of human lambda light chain constant region (Xi, A2, 3, X ), which are encoded by the genes IGLC1, IGCL2, IGLC3, and IGLC7. The “class” of an antibody or immunoglobulin refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, 5, e, y, and p, respectively.

[0259] An exemplary immunoglobulin (antibody) structural unit is composed of two pairs of polypeptide chains, each pair having one “light” (about 25 kD) and one “heavy” chain (about 50-70 kD). The N-terminal domain of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chain domains, respectively. The IgGl heavy chain comprises the VH, CHI, CH2, and CH3 domains, respectively from the N- to C-terminus. The light chain comprises the VL and CL domains from N to C terminus. The IgGl heavy chain comprises a hinge between the CHI and CH2 domains. In certain embodiments, the immunoglobulin constructs comprise at least one immunoglobulin domain from IgG, IgM, IgA, IgD, or IgE connected to a therapeutic polypeptide. In some embodiments, the immunoglobulin domain found in an antibody provided herein, is from or is derived from an immunoglobulin-based construct such as a diabody or a nanobody. In certain embodiments, the immunoglobulin constructs described herein comprise at least one immunoglobulin domain from a heavy chain antibody such as a camelid antibody. In certain embodiments, the immunoglobulin constructs provided herein comprise at least one immunoglobulin domain from a mammalian antibody such as a bovine antibody, a human antibody, a camelid antibody, a mouse antibody or any chimeric antibody.

[0260] In some embodiments, the antibodies provided herein comprise a heavy chain. In one embodiment, the heavy chain is an IgA. In one embodiment, the heavy chain is an IgD. In one embodiment, the heavy chain is an IgE. In one embodiment, the heavy chain is an IgG. In one embodiment, the heavy chain is an IgM. In one embodiment, the heavy chain is an IgGl. In one embodiment, the heavy chain is an IgG2. In one embodiment, the heavy chain is an IgG3. In one embodiment, the heavy chain is an IgG4. In one embodiment, the heavy chain is an IgAl. In one embodiment, the heavy chain is an IgA2.AOJ-012PCAOE-0106WO

[0261] In some embodiments, an antibody is an IgGl antibody. In some embodiments, an antibody is an IgG3 antibody. In some embodiments, an antibody is an IgG2 antibody. In some embodiments, an antibody is an IgG4 antibody.

[0262] Generally, native four-chain antibodies comprise six hypervariable regions (HVRs); three in the VH (Hl, H2, and H3), and three in the VL (LI, L2, and L3). HVRs generally comprise amino acid residues from the hypervariable loops and / or from the complementarity determining regions (CDRs), the latter being of highest sequence variability and / or involved in antigen recognition. With the exception of CDR1 in VH, CDRs generally comprise the amino acid residues that form the hypervariable loops. Hypervariable regions (HVRs) are also referred to as “complementarity determining regions” (CDRs), and these terms are used herein interchangeably in reference to portions of the variable region that form the antigen-binding regions. This particular region has been described by Kabat et al., U.S. Dept, of Health and Human Services, Sequences of Proteins of Immunological Interest (1983) and by Chothia et al. (1987) J Mol Biol 196:901-917, where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.

[0263] The amino acid sequence boundaries of a CDR can be determined by one of skill in the art using any of a number of known numbering schemes, including those described by Kabat et al., supra (“Kabat” numbering scheme); Al-Lazikani et al. (1997) J. Mol. Biol., l'i'.921 -948 (“Chothia” numbering scheme); MacCallum et al. (1996) J. Mol. Biol. 262:732- 745 (“Contact” numbering scheme); Lefranc et al. (2003) Dev. Comp. Immunol. 27:55-77 (“IMGT” numbering scheme); and Honegge and Pliickthun (2001) J. Mol. Biol. 309:657-70 (“AHo” numbering scheme); each of which is incorporated by reference in its entirety.

[0264] TABLE 2 provides the positions of CDR-L 1 , CDR-L2, CDR-L3 , CDR-H 1 , CDR- H2, and CDR-H3 as identified by the Kabat and Chothia schemes. For CDR-H 1, residue numbering is provided using both the Kabat and Chothia numbering schemes.

[0265] CDRs may be assigned, for example, using antibody numbering software, such as Abnum, available at www.bioinf.org.uk / abs / abnum / , and described in Abhinandan and Martin, Immunology, 2008, 45:3832-3839, incorporated by reference in its entirety.AOJ-012PCAOE-0106WOTABLE 2. Residues in CDRs according to Kabat and Chothia numbering schemes* The C-terminus of CDR-H1, when numbered using the Kabat numbering convention, varies between H32 and H34, depending on the length of the CDR.

[0266] The “EU numbering scheme” is generally used when referring to a residue in an antibody heavy chain constant region (e.g., as reported in Kabat et al., supra). Unless stated otherwise, the EU numbering scheme is used to refer to residues in antibody heavy chain constant regions described herein.

[0267] One example of an antigen-binding domain is an antigen-binding domain formed by a VH-VL dimer of an antibody. Another example of an antigen-binding domain is an antigen-binding domain formed by diversification of certain loops from the tenth fibronectin type III domain of an Adnectin. An antigen-binding domain can include CDRs 1, 2, and 3 from a heavy chain in that order; and CDRs 1, 2, and 3 from a light chain in that order.

[0268] Epitopes frequently consist of surface-accessible amino acid residues and / or sugar side chains and may have specific three-dimensional structural characteristics, as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished in that the binding to the former but not the latter may be lost in the presence of denaturing solvents. An epitope may comprise amino acid residues that are directly involved in the binding, and other amino acid residues, which are not directly involved in the binding. The epitope to which an antibody binds can be determined using known techniques for epitope determination such as, for example, testing for antibody binding to TSLP or IL- 13, to TSLP or IL- 13 variants with different point-mutations, or to chimeric TSLP or IL- 13 variants.

[0269] To screen for antibodies which bind to an epitope on a target antigen bound by an antibody of interest (e.g., TSLP and / or IL-13), a routine cross-blocking assay such as that described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988), can be performed. Alternatively, or additionally, epitope mapping can be performed by methods known in the art.AOJ-012PCAOE-0106WO

[0270] Anti- TSLP and anti- IL- 13 antibodies can include those described herein such as the clones set forth in the drawings and / or tables. In some embodiments, the antibody comprises an alternative scaffold. In some embodiments, the antibody consists of an alternative scaffold. In some embodiments, the antibody consists essentially of an alternative scaffold. In some embodiments, the antibody comprises an antibody fragment. In some embodiments, the antibody consists of an antibody fragment. In some embodiments, the antibody consists essentially of an antibody fragment.

[0271] In some embodiments, the antibodies are monoclonal antibodies.

[0272] In some embodiments, the antibodies are polyclonal antibodies.

[0273] In some embodiments, the antibodies are produced by hybridomas. In other embodiments, the antibodies are produced by recombinant cells engineered to express the desired variable and constant domains.

[0274] In some embodiments, the antibodies may be single chain antibodies or other antibody derivatives retaining the antigen specificity and the lower hinge region or a variant thereof.

[0275] In some embodiments, the antibodies may be polyfunctional antibodies, recombinant antibodies, fully human antibodies, humanized antibodies, fragments or variants thereof. In particular embodiments, the antibody fragment or a derivative thereof is selected from a Fab fragment, a Fab'2 fragment, a CDR and scFv.Anti-TSLP Antibodies

[0276] The present application provides antibodies or antigen binding fragments thereof and compositions comprising an antibody, or an antigen binding fragment thereof, which binds TSLP. In some embodiments, an anti-TSLP antibody, or antigen binding fragment thereof, described herein is selected from tezepelumab, GR2002 (described in US Patent Application Publication No. US20240132581, which is incorporated herein by reference), TQC2731 (also known as BSI-045B and bosakitug, described in US Patent Application Publication No. US20220289833, which is incorporated herein by reference), solrikitug, hu23bl2 (described in U.S. Patent No. 8,232,372, which is incorporated herein by reference), 43B1-H2L2 (described in U.S. Patent Application Publication No. US20220363781, which is incorporated herein by reference), and 43B1-H6L1 (also described in U.S. Patent Application Publication No. US20220363781) or a variant thereof comprising an Fc region with one or more amino acid substitutions as described herein. In some embodiments, tezepelumab comprises a variable heavy (VH) chain sequence having the amino acid sequence of SEQ IDAOJ-012PCAOE-0106WONO: 34 and a variable light (VL) chain sequence having the amino acid sequence of SEQ ID NO: 411. In some embodiments, TQC2731 comprises a VH chain sequence having the amino acid sequence of SEQ ID NO: 528 and a VL chain sequence having the amino acid sequence of SEQ ID NO: 529. In some embodiments, solrikitug comprises a VH chain sequence having the amino acid sequence of SEQ ID NO: 536 and a VL chain sequence having the amino acid sequence of SEQ ID NO: 537. In some embodiments, hu23bl2 comprises a VH chain sequence having the amino acid sequence of SEQ ID NO: 412 and a VL chain sequence having the amino acid sequence of SEQ ID NO: 413. In some embodiments, 43B1- H2L2 comprises a VH chain sequence having the amino acid sequence of SEQ ID NO: 414 and a VL chain sequence having the amino acid sequence of SEQ ID NO: 415. In some embodiments, 43B 1-H6E1 comprises a VH chain sequence having the amino acid sequence of SEQ ID NO: 416 and a VL chain sequence having the amino acid sequence of SEQ ID NO: 417. In some embodiments, tezepelumab comprises a heavy chain having the amino acid sequence of SEQ ID NO: 489 and a light chain sequence having the amino acid sequence of SEQ ID NO: 490. In some embodiments, TQC2731 comprises a heavy chain having the amino acid sequence of SEQ ID NO: 526 and a light chain sequence having the amino acid sequence of SEQ ID NO: 527. In some embodiments, solrikitug comprises a heavy chain having the amino acid sequence of SEQ ID NO: 538 and a light chain sequence having the amino acid sequence of SEQ ID NO: 539. In some embodiments, hu23bl2 comprises a heavy chain having the amino acid sequence of SEQ ID NO: 530 and a light chain sequence having the amino acid sequence of SEQ ID NO: 531. In some embodiments, 43B1-H2L2 comprises a heavy chain having the amino acid sequence of SEQ ID NO: 532 and a light chain sequence having the amino acid sequence of SEQ ID NO: 533. In some embodiments, 43B1-H6L1 comprises a heavy chain having the amino acid sequence of SEQ ID NO: 534 and a light chain sequence having the amino acid sequence of SEQ ID NO: 535. Additional anti-TSLP antibodies are described in PCT Application No. PCT / US2025 / 034623, which is incorporated herein by reference in its entirety. In some embodiments, an anti-TSLP antibody, or antigen binding fragment thereof, described herein is selected from an anti-TSLP antibody, or antigen binding fragment thereof, described therein. Further TSLP antibodies are described in U.S. Patent No. 8,232,372 and U.S. Patent Application Publication No. US20220363781, each of which is incorporated herein by reference in its entirety.

[0277] Sequences of exemplary anti-TSLP antibodies, or antigen binding fragments thereof, are provided in TABLE 3, TABLE 4, TABLE 5, and TABLE 6.AOJ-012-2AOE-0106WOAOJ-012-2AOE-0106WOSequences of Exemplary Anti-TSLP AntibodiesTABLE 3. Sequences of anti-TSLP antibody constructs - CDRsAOJ-012-2AOE-0106WOAOJ-012-2AOE-0106WOAOJ-012-2AOE-0106WOAOJ-012-2AOE-0106WOAOJ-012-2AOE-0106WOAOJ-012-2AOE-0106WOAOI-012-2AOE-0106WOAOI-012-2AOE-0106WOAOJ-012-2AOE-0106WOAOJ-012PCAOE-OW6WOTABLE 4. Sequences of anti-TSLP antibody constructs - VH and VLAOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOTABLE 5. Sequences of additional anti-TSLP antibody constructs - CDRsAOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOTABLE 6. Sequences of additional anti-TSLP antibody constructs - VH / VI.AOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOAnti-TSLP VH Domains

[0278] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence selected from any one of SEQ ID NOs: 32-36 and 418.

[0279] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a VH sequence provided in any one of SEQ ID NOs: 32-36 and 418. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence provided in any one of SEQ ID NOs: 32- 36 and 418, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.'’ In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.Anti-TSLP VL Domains

[0280] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VL sequence selected from any one of SEQ ID NOs: 37-45, 361-397, and 544-557.

[0281] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in any one of SEQ ID NO: 37-45, 361-397, and 544-557. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VL sequence provided in any one of SEQ ID NO: 37-45, 361-397, and 544-557, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directedAOJ-012PCAOE-0106WO mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.Anti-TSLP VH-VL Combinations

[0282] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence selected from any one of SEQ ID NOs: 32-36 and 418; and a VL sequence selected from any one of SEQ ID NOs: 37-45, 361-397, and 544-557.

[0283] In certain aspects, any one of SEQ ID NOs: 32-36 and 418 can be combined with any one of SEQ ID NOs: 37-45, 361-397, and 544-557.

[0284] In certain aspects, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence and a VL sequence of a construct provided in TABLE 4 (e.g., a VH sequence and a VL sequence from the same row of TABLE 4). In certain aspects, an antibody, or an antigen binding fragment thereof, provided herein comprises a VH sequence and a VL sequence of a construct provided in TABLE 6 (e.g., a VH sequence and a VL sequence from the same row of TABLE 6).

[0285] In certain aspects, an antibody, or an antigen binding fragment thereof, provided herein comprises a VH sequence and a VL sequence of a construct provided in PCT Application No. PCT / US2025 / 034623, incorporated by reference herein in its entirety. In certain aspects, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence and a VL sequence from Table 4 or Table 11 in PCT Application No.PCT / US2025 / 034623 (e.g., a VH sequence and a VL sequence from the same row of Table 4 or Table 11).

[0286] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in any one of SEQ ID NOs: 32-36 and 418: and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in any one of SEQ ID NOs: 37-45, 361-397, and 544-557. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence provided in any one of SEQ ID NOs: 32-36 and 418, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions, and a VL sequence provided in any one of SEQ IDAOJ-012PCAOE-0106WONOs: 37-45, 361-397, and 544-557, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

[0287] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 32 and a VL sequence set forth in SEQ ID NO: 37.

[0288] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 33 and a VL sequence set forth in SEQ ID NO: 38.

[0289] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 418 and a VL sequence set forth in SEQ ID NO: 39.

[0290] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 33 and a VL sequence set forth in SEQ ID NO: 40.

[0291] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41.

[0292] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 35 and a VL sequence set forth in SEQ ID NO: 42.

[0293] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 43.

[0294] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 32 and a VL sequence set forth in SEQ ID NO: 44.AOJ-012PCAOE-0106WO

[0295] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 36 and a VL sequence set forth in SEQ ID NO: 45.

[0296] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 374.

[0297] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 380.

[0298] In certain embodiments of any of the antibodies, or antigen binding fragments thereof, described above, the antibody further comprises a heavy chain comprising a human IgG sequence selected from a sequence set forth in any one of SEQ ID NOs: 47-270. In certain embodiments, the heavy chain comprises a human IgG sequence selected from SEQ ID NO: 61 and SEQ ID NO: 173.

[0299] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 34; and a VL sequence set forth in SEQ ID NO: 41; and the antibody further comprises a heavy chain comprising a human IgG sequence selected from a sequence set forth in any one of SEQ ID NOs: 47-270. In certain embodiments, the heavy chain comprises a human IgG sequence selected from SEQ ID NO: 61 and SEQ ID NO: 173. In certain embodiments of any of the antibodies, or antigen binding fragments thereof, described above, the antibody further comprises a constant light chain sequence comprising a sequence set forth in SEQ ID NO: 495.

[0300] Although the antibody may be produced using a polynucleotide sequence that encodes a constant heavy chain region containing a C-terminal lysine (e.g., a sequence encoding any one of SEQ ID NOs: 159-270), the C-terminal lysine may be cleaved off during manufacture or after administration (resulting in, e.g., an antibody containing a constant heavy chain sequence of any one of SEQ ID NOs: 47-158). Accordingly, any of the antibodies or antigen binding fragments thereof described above may comprise a human IgG sequence containing a C-terminal lysine (e.g., any one of SEQ ID NOs: 159-270), a human IgG sequence lacking a C-terminal lysine (e.g., any one of SEQ ID NOs: 47-158), or a mixture thereof (e.g., a mixture of the same heavy chain constant region sequence with and without a C-terminal lysine, such as a mixture of SEQ ID NO: 173 and SEQ ID NO: 61).AOJ-012PCAOE-0106WO

[0301] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 34, a VL sequence set forth in SEQ ID NO: 41, a heavy chain constant region e.g., an IgGl constant region) comprising LALA / YTE substitutions, and a human lambda light chain constant region (e.g., a lambda light chain constant region of subtype 1, 2, 3, or 7, such as a lambda light chain constant region set forth in any one of SEQ ID NOs: 495-498). In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 34, a VL sequence set forth in SEQ ID NO: 41, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 495. In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 34; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 41, a heavy chain constant region {e.g., an IgGl constant region) comprising LALA / YTE substitutions, and a human lambda light chain constant region (e.g., a lambda light chain constant region of subtype 1, 2, 3, or 7, such as a lambda light chain constant region set forth in any one of SEQ ID NOs: 495-498). In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 34; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 41, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173 or a sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 495 or a sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 495.

[0302] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 34, a VL sequence set forth in SEQ ID NO: 41, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 495. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 34, a VL sequence set forth in SEQ ID NO: 41, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO:AOJ-012PCAOE-0106WO495. In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 499 and / or 501 and a light chain sequence set forth in SEQ ID NO: 500. In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 499 and a light chain sequence set forth in SEQ ID NO: 500. The heavy chain sequence of SEQ ID NO: 499 contains a C-terminal lysine, which may be cleaved off during manufacture or after administration, resulting in an antibody containing the heavy chain sequence of SEQ ID NO: 501.

[0303] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 34, a VL sequence set forth in SEQ ID NO: 43, a heavy chain constant region (e.g., an IgGl constant region) comprising LALA / YTE substitutions, and a human lambda light chain constant region (e.g., a lambda light chain constant region of subtype 1, 2, 3, or 7, such as a lambda light chain constant region set forth in any one of SEQ ID NOs: 495-498). In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 34, a VL sequence set forth in SEQ ID NO: 43, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 495. In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 34; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 43, a heavy chain constant region (e.g., an IgGl constant region) comprising LALA / YTE substitutions, and a human lambda light chain constant region (e.g., a lambda light chain constant region of subtype 1, 2, 3, or 7, such as a lambda light chain constant region set forth in any one of SEQ ID NOs: 495-498). In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 34; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 43, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173 or a sequence having at least about 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 495 or a sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 495.AOJ-012PCAOE-0106WO

[0304] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 34, a VL sequence set forth in SEQ ID NO: 43, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 495. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 34, a VL sequence set forth in SEQ ID NO: 43, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 495. In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 502 and a light chain sequence set forth in SEQ ID NO: 503. The heavy chain sequence of SEQ ID NO: 502 contains a C-terminal lysine, which may be cleaved off during manufacture or after administration.Anti-TSLP CDRs

[0305] In some embodiments, disclosed herein is an antibody, or antigen binding fragment thereof, comprising 1 , 2, 3, 4, 5, or 6 of the CDRs of TABLE 3. In some embodiments, disclosed herein is an antibody, or antigen binding fragment thereof, comprising 6 of the Kabat CDRs of TABLE 3, 6 of the Chothia CDRs of TABLE 3, or 6 of the IMGT CDRs of TABLE 3. In some embodiments, the antibody, or antigen binding fragment thereof, comprises 6 of the Kabat CDRs, 6 of the Chothia CDRs, or 6 of the IMGT CDRs from a single row of TABLE 3 (e.g., 6 CDRs from the same antibody).

[0306] In some embodiments, disclosed herein is an antibody, or an antigen binding fragment thereof, comprising 1, 2, 3, 4, 5, or 6 of the CDRs of TABLE 5. In some embodiments, disclosed herein is an antibody, or an antigen binding fragment thereof, comprising 6 of the Kabat CDRs of TABLE 5, 6 of the Chothia CDRs of TABLE 5, or 6 of the IMGT CDRs of TABLE 5. In some embodiments, the antibody, or an antigen binding fragment thereof, comprises 6 of the Kabat CDRs, 6 of the Chothia CDRs, or 6 of the IMGT CDRs from a single row of TABLE 5 (e.g., 6 CDRs from the same antibody).

[0307] In some embodiments, disclosed herein is an antibody, or an antigen binding fragment thereof, comprising 1, 2, 3, 4, 5, or 6 of the CDRs of an antibody provided in PCT Application No. PCT / US2025 / 034623, incorporated by reference herein in its entirety, such as 1, 2, 3, 4, 5, or 6 of the CDRs in Table 3 or Table 10 in PCT Application No. PCT / US2025 / 034623. In some embodiments, disclosed herein is an antibody, or an antigenAOJ-012PCAOE-OW6WO binding fragment thereof, comprising 1, 2, 3, 4, 5, or 6 of the Kabat CDRs of an antibody, or an antigen binding fragment thereof, provided in PCT Application No. PCT / US 2025 / 034623. In some embodiments, disclosed herein is an antibody, or an antigen binding fragment thereof, comprising 1, 2, 3, 4, 5, or 6 of the Chothia CDRs of an antibody, or an antigen binding fragment thereof, provided in PCT Application No. PCT / US2025 / 034623. In some embodiments, disclosed herein is an antibody, or an antigen binding fragment thereof, comprising 1, 2, 3, 4, 5, or 6 of the IMGT CDRs of an antibody provided in PCT Application No. PCT / US2025 / 034623. In some embodiments, the antibody, or an antigen binding fragment thereof, comprises 6 of the Kabat CDRs, 6 of the Chothia CDRs, or 6 of the IMGT CDRs from a single row of Table 3 or Table 10 in in PCT Application No. PCT / US2025 / 034623 (e.g., 6 CDRs from the same antibody).

[0308] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises one to three CDRs of a VH domain selected from any one of SEQ ID NOs: 32-36 and 418. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises two to three CDRs of a VH domain selected from any one of SEQ ID NOs: 32-36 and 418. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises three CDRs of a VH domain selected from any one of SEQ ID NOs: 32-36 and 418. In some aspects, the CDRs are Kabat CDRs. In some aspects, the CDRs are Chothia CDRs. In some aspects, the CDRs are IMGT CDRs. In some aspects, the CDRs are AbM CDRs. In some aspects, the CDRs are Contact CDRs.

[0309] In some embodiments, the CDRs are CDRs having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to a CDR-H1, CDR-H2, or CDR-H3 selected from SEQ ID NOs: 1-18. In some embodiments, the CDR-H1 is a CDR-H1 of a VH domain selected from any one of SEQ ID NOs: 32-36 and 418, with up to 1, 2, 3, 4, or 5 amino acid substitutions. In some embodiments, the CDR-H2 is a CDR-H2 of a VH domain selected from any one of SEQ ID NOs: 32-36 and 418, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the CDR-H3 is a CDR-H3 of a VH domain selected from any one of SEQ ID NOs: 32-36 and 418, with up to I, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants." In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In someAOJ-012PCAOE-0106WO embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

[0310] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises one to three CDRs of a VL domain selected from any one of SEQ ID NOs: 37-45, 361-397, and 544-557. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises two to three CDRs of a VL domain selected from any one of SEQ ID NOs: 37-45, 361-397, and 544-557. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises three CDRs of a VL domain selected from any one of SEQ ID NOs: 37-45, 361-397, and 544-557. In some aspects, the CDRs are Kabat CDRs. In some aspects, the CDRs are Chothia CDRs. In some aspects, the CDRs are IMGT CDRs. In some aspects, the CDRs are AbM CDRs. In some aspects, the CDRs are Contact CDRs.

[0311] In some embodiments, the CDRs are CDRs having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to a CDR-LL CDR-L2, or CDR-L3 selected from SEQ ID NOs: 19-31 , 304-360, 540-543, and 564 and the amino acid sequences DVS, DDS, EDS, DDT, DDK, DDL, and DDN. In some embodiments, the CDR- L1 is a CDR-L1 of a VL domain selected from any one of SEQ ID NOs: 37-45, 361-397, and 544-557, with up to 1, 2, 3, 4, or 5 amino acid substitutions. In some embodiments, the CDR- L2 is a CDR-L2 of a VL domain selected from any one of SEQ ID NOs: 37-45, 361-397, and 544-557, with up to I, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the CDR-L3 is a CDR-L3 of a VL domain selected from any one of SEQ ID NOs: 37-45, 361-397, and 544-557, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

[0312] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises one to three CDRs of a VH domain selected from any one of SEQ ID NOs: 32-36 and 418 and one to three CDRs of a VL domain selected from any one of SEQ IDAOJ-012PCAOE-0106WONOs: 37-45, 361-397, and 544-557. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises two to three CDRs of a VH domain selected from any one of SEQ ID NOs: 32-36 and 418 and two to three CDRs of a VL domain selected from any one of SEQ ID NOs: 37-45, 361-397, and 544-557. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises three CDRs of a VH domain selected from any one of SEQ ID NOs: 32-36 and 418 and three CDRs of a VL domain selected from any one of SEQ ID NOs: 37-45, 361-397, and 544-557. In some aspects, the CDRs are Kabat CDRs. In some aspects, the CDRs are Chothia CDRs. In some aspects, the CDRs are IMGT CDRs. In some aspects, the CDRs are AbM CDRs. In some aspects, the CDRs are Contact CDRs.

[0313] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H3 selected from any one of SEQ ID NOs: 13-18. In some aspects, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H3 selected from any one of SEQ ID NOs: 13-18. In some embodiments, the CDR-H3 is a CDR-H3 selected from any one of SEQ ID NO: 13-18, with up to 1 , 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

[0314] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 selected from any one of SEQ ID NOs: 1-9. In some aspects, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H1 selected from any one of SEQ ID NOs: 1-9. In some embodiments, the CDR-H1 is a CDR-H1 selected from any one of SEQ ID NO: 1-9, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein.AOJ-012PCAOE-0106WOIn some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

[0315] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H2 selected from any one of SEQ ID NOs: 10-12. In some aspects, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H2 selected from any one of SEQ ID NOs: 10-12. In some embodiments, the CDR-H2 is a CDR-H2 selected from any one of SEQ ID NOs: 10-12, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

[0316] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-L3 selected from any one of SEQ ID NOs: 27-31, 344-360, and 540-543. In some aspects, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L3 selected from any one of SEQ ID NOs: 27-31, 344-360, and 540-543. In some embodiments, the CDR-L3 is a CDR-L3 selected from any one of SEQ ID NOs: 27-31, 344-360, and 540-543, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de. novo according to the methods provided herein for obtaining antibodies.

[0317] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-L2 selected from any one of SEQ ID NOs: 25-26, 336-343, and the amino acid sequences DDS, DVS, EDS, DDT, DDK, DDL, and DDN. In some aspects, theAOJ-012PCAOE-0106WOCDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%. 98%. or 99% identity to a CDR-L2 selected from any one of SEQ ID NOs: 25-26, 336-343, and the amino acid sequences DDS, DVS, EDS, DDT, DDK, DDL, and DDN. In some embodiments, the CDR-L2 is a CDR-L2 selected from any one of SEQ ID NOs: 25-26, 336-343, and the amino acid sequences DDS, DVS, EDS, DDT, DDK, DDL, and DDN, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

[0318] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-L1 selected from any one of SEQ ID NOs: 19-24, 304-335, and 564. In some aspects, the CDR-L1 has at least about 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L1 selected from any one of SEQ ID NOs: 19-24, 304- 335, and 564. In some embodiments, the CDR-L1 is a CDR-L1 selected from any one of SEQ ID NOs: 19-24, 304-335, and 564, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

[0319] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H3 selected from any one of SEQ ID NOs: 1 -18, a CDR-H2 selected from any one of SEQ ID NOs: 10-12, a CDR-H1 selected from any one of SEQ ID NOs: 1-9, a CDR-L3 selected from any one of SEQ ID NOs: 27-31, 344-360, and 540-543, a CDR-L2 selected from any one of SEQ ID NOs: 25-26, 336-343, and the amino acid sequences DDS, DVS, EDS, DDT, DDK, DDL, and DDN, and a CDR-L1 selected from anyAOJ-012PCAOE-0106WO one of SEQ ID NOs: 19-24, 304-335, and 564. In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%. 92%. 93%. 94%. 95%. 96%. 97%. 98%. or 99% identity to a CDR-H3 selected from any one of SEQ ID NOs: 13-18, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% ,or 99% identity to a CDR-H2 selected from any one of SEQ ID NOs: 10-12, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H1 selected from any one of SEQ ID NOs: 1-9, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L3 selected from any one of SEQ ID NOs: 27-31, 344-360, and 540-543, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L2 selected from any one of SEQ ID NOs: 25-26, 336-343, and the amino acid sequences DDS, DVS, EDS, DDT, DDK, DDL, and DDN, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L1 selected from any one of SEQ ID NOs: 19-24, 304-335, and 564. In some embodiments, the CDR-H3 is a CDR-H3 selected from any one of SEQ ID NOs: 13-18, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR-H2 selected from any one of SEQ ID NOs: 10-12, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H1 is a CDR-H1 selected from any one of SEQ ID NOs: 1-9, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 selected from any one of SEQ ID NOs: 27-31, 344-360, and 540-543, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L2 is a CDR-L2 selected from any one of SEQ ID NOs: 25-26, 336-343, and the amino acid sequences DDS, DVS, EDS, DDT, DDK, DDL, and DDN, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 selected from any one of SEQ ID NOs: 19-24, 304-335, and 564, with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions.

[0320] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 21 and 24; a CDR- L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27. In some embodiments, the CDR-H3 has at least about 80%, 90%. 91%. 92%. 93%. 94%. 95%. 96%. 97%, 98%. or 99% identity to a CDR-H3 selected from any one of SEQ ID NOs: 13 and 16, the CDR-H2AOJ-012PCAOE-0106WO has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H2 selected from any one of SEQ ID NOs: 10, 11, and 12, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H1 selected from any one of SEQ ID NOs: 3, 6, and 9, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L3 of SEQ ID NO: 27, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%. 98%. or 99% identity to a CDR-L2 set forth in SEQ ID NO: 26 or the amino acid sequence DDS, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L1 selected from any one of SEQ ID NOs: 21 and 24. In some embodiments, the CDR-H3 is a CDR-H3 selected from any one of SEQ ID NOs: 13 and 16, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR-H2 selected from any one of SEQ ID NOs: 10, 1 1, and 12, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H1 is a CDR-H1 selected from any one of SEQ ID NOs: 3, 6, and 9, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 set forth in SEQ ID NO: 27 with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L2 is a CDR-L2 set forth in SEQ ID NO: 26 or the amino acid sequence DDS, with up to 1 , 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 selected from any one of SEQ ID NOs: 21 and 24, with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions.

[0321] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 21 and 24; a CDR- L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27.

[0322] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 19 and 22; a CDR- L2 comprising the sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 30. In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, orAOJ-012PCAOE-0106WO99% identity to a CDR-H3 selected from any one of SEQ ID NOs: 13 and 16, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H2 selected from any one of SEQ ID NOs: 10, 11, and 12, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H1 selected from any one of SEQ ID NOs: 3, 6, and 9, the CDR-L3 has at least about 80%, 90%, 91%. 92%. 93%. 94%. 95%, 96%, 97%, 98%, or 99% identity to a CDR-L3 set forth in SEQ ID NO: 30, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L2 set forth in SEQ ID NO: 25 and the amino acid sequence DVS, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L1 selected from any one of SEQ ID NOs: 19 and 22. In some embodiments, the CDR-H3 is a CDR-H3 selected from any one of SEQ ID NOs: 13 and 16, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR- H2 selected from any one of SEQ ID NOs: 10, 11, and 12, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions: the CDR-H1 is a CDR-H1 selected from any one of SEQ ID NOs: 3, 6, and 9, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 set forth in SEQ ID NO: 30 with up to 1 , 2, 3, 4, or 5 amino acid substitutions; the CDR-L2 is a CDR-L2 set forth in SEQ ID NO: 25 or the amino acid sequence DVS, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 selected from any one of SEQ ID NOs: 19 and 22, with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions.

[0323] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 19 and 22; a CDR- L2 comprising the sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 30.

[0324] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 1 1, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 310 and 324; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 351. In someAOJ-012PCAOE-0106WO embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H3 selected from any one of SEQ ID NOs: 13 and 16, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H2 selected from any one of SEQ ID NOs: 10, 11, and 12, the CDR- H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H1 selected from any one of SEQ ID NOs: 3, 6, and 9, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L3 set forth in SEQ ID NO: 351, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L2 set forth in SEQ ID NO: 26 or the amino acid sequence DDS, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L1 selected from any one of SEQ ID NOs: 310 and 324. In some embodiments, the CDR-H3 is a CDR-H3 selected from any one of SEQ ID NOs: 13 and 16, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions: the CDR-H2 is a CDR-H2 selected from any one of SEQ ID NOs: 10, 11, and 12, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions: the CDR-H1 is a CDR-H1 selected from any one of SEQ ID NOs: 3, 6, and 9, with up to 1 , 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 set forth in SEQ ID NO: 351 with up to 1, 2, 3, 4, or5 amino acid substitutions; the CDR-L2 is a CDR-L2 set forth in SEQ ID NO: 26 or the amino acid sequence DDS, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 selected from any one of SEQ ID NOs: 310 and 324, with up to 1, 2, 3, 4, 5, or6 amino acid substitutions.

[0325] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NO: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 310 and 324; a CDR- L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 351.

[0326] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 315 and 331; aAOJ-012PCAOE-0106WOCDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 355. In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H3 selected from any one of SEQ ID NOs: 13 and 16, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H2 selected from any one of SEQ ID NOs: 10, 11, and 12, the CDR- H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H1 selected from any one of SEQ ID NOs: 3, 6, and 9, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L3 set forth in SEQ ID NO: 355, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L2 set forth in SEQ ID NO: 26 or the amino acid sequence DDS, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L1 selected from any one of SEQ ID NOs: 315 and 331. In some embodiments, the CDR-H3 is a CDR-H3 selected from any one of SEQ ID NOs: 13 and 16, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR-H2 selected from any one of SEQ ID NOs: 10, 11 , and 12, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H1 is a CDR-H1 selected from any one of SEQ ID NOs: 3, 6, and 9, with up to 1, 2, 3, 4, or 5 amino acid substitutions: the CDR-L3 is a CDR-L3 set forth in SEQ ID NO: 355 with up to 1, 2, 3, 4, or5 amino acid substitutions; the CDR-L2 is a CDR-L2 set forth in SEQ ID NO: 26 or the amino acid sequence DDS, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 selected from any one of SEQ ID NOs: 315 and 331, with up to 1, 2, 3, 4, 5, or6 amino acid substitutions.

[0327] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NO: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 315 and 331; a CDR- L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 355.

[0328] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, and 7, a CDR-H2 comprising an amino acid sequence set forth in any one ofAOJ-012PCAOE-0106WOSEQ ID NOs: 10, 11, and 12, a CDR-H3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 13 and 16, a CDR-L1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 19 and 22, a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS, and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 27.

[0329] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2, 5, and 8, a CDR-H2 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 10, 11, and 12, a CDR-H3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 13 and 16, a CDR-L1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 19 and 22, a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS, and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 28.

[0330] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2, 5, and 8, a CDR-H2 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 10, 11, and 12, a CDR-H3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 14 and 17, a CDR-L1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 20 and 23, a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS, and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 28.

[0331] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2, 5, and 8, a CDR-H2 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 10, 11, and 12, a CDR-H3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 13 and 16, a CDR-L1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 21 and 24, a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS, and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 28.

[0332] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 3, 6, and 9, a CDR-H2 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 10, 11, and 12, a CDR-H3 comprising an amino acid sequence set forth in anyAOJ-012PCAOE-0106WO one of SEQ ID NOs: 15 and 18, a CDR-L1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 21 and 24, a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS, and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 29.

[0333] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 1, 4, and 7, a CDR-H2 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 10, 11, and 12, a CDR-H3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 13 and 16, a CDR-L1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 19 and 22, a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS, and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 31.

[0334] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 2, 5, and 8, a CDR-H2 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 10, 1 1 , and 12, a CDR-H3 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 15 and 18, a CDR-L1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 21 and 24, a CDR-L2 comprising an amino acid sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS, and a CDR-L3 comprising an amino acid sequence set forth in SEQ ID NO: 28.

[0335] In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H3 of TABLE 3, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H2 of TABLE 3, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H1 of TABLE 3, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L3 of TABLE 3, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L2 of TABLE 3, and the CDR-L1 has at least about 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L1 of TABLE 3. In some embodiments, the CDR-H3 is a CDR-H3 of TABLE 3, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR-H2 of TABLE 3, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H1 is a CDR-H1 of TABLE 3, with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 of TABLE 3 with upAOJ-012PCAOE-0106WO to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L2 is a CDR-L2 of TABLE 3, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 of TABLE 3, with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions.

[0336] In some embodiments, the CDR-H3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H3 of TABLE 5, the CDR-H2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H2 of TABLE 5, the CDR-H1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-H1 of TABLE 5, the CDR-L3 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L3 of TABLE 5, the CDR-L2 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L2 of TABLE 5, and the CDR-L1 has at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a CDR-L1 of TABLE 5. In some embodiments, the CDR-H3 is a CDR-H3 of TABLE 5, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H2 is a CDR-H2 of TABLE 5, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; the CDR-H1 is a CDR-H1 of TABLE 5, with up to 1 , 2, 3, 4, or 5 amino acid substitutions; the CDR-L3 is a CDR-L3 of TABLE 5 with up to 1, 2, 3, 4, or 5 amino acid substitutions; the CDR-L2 is a CDR-L2 of TABLE 5, with up to 1, 2, 3, or 4 amino acid substitutions; and the CDR-L1 is a CDR-L1 of TABLE 5, with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions.

[0337] In certain embodiments of any of the antibodies, or antigen binding fragments thereof, described above, the antibody further comprises a heavy chain comprising a human IgG sequence selected from a sequence set forth in any of SEQ ID NOs: 47-270. In certain embodiments of any of the antibodies, or antigen binding fragments thereof, described above, the antibody further comprises a constant light chain sequence comprising a sequence set forth in SEQ ID NO: 495. In certain embodiments of any of the antibodies, or antigen binding fragments thereof, described above, the antibody further comprises a heavy chain comprising a human IgG sequence selected from SEQ ID NO: 61 or SEQ ID NO: 173 and a constant light chain sequence comprising a sequence set forth in SEQ ID NO: 495. In certain embodiments of any of the antibodies, or antigen binding fragments thereof, described above, the antibody comprises a heavy chain comprising a human IgG sequence set forth in SEQ ID NO: 173 and a constant light chain sequence comprising a sequence set forth in SEQ ID NO: 495.AOJ-012PCAOE-0106WO

[0338] In some embodiments, the antibody, or antigen binding fragment thereof, comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 21 and 24; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26 or the amino acid sequence DDS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27. In certain embodiments, the antibody, or antigen binding fragment thereof, further comprises a heavy chain constant region (e.g., an IgGl constant region) comprising LALA / YTE substitutions. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain comprising a heavy chain constant region selected from SEQ ID NO: 61 and SEQ ID NO: 173. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain comprising a heavy chain constant region set forth in SEQ ID NO: 173. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a human lambda light chain constant region (e.g., a lambda light chain constant region of subtype 1, 2, 3, or 7, such as a lambda light chain constant region set forth in any one of SEQ ID NOs: 495-498). In some embodiments, the antibody, or antigen binding fragment thereof, comprises a constant light chain sequence comprising a sequence set forth in SEQ ID NO: 495.

[0339] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a CDR-H1 comprising the sequence set forth in any one of SEQ ID NOs: 3, 6, and 9; a CDR-H2 comprising the sequence set forth in any one of SEQ ID NOs: 10, 11, and 12; a CDR-H3 comprising the sequence set forth in any one of SEQ ID NOs: 13 and 16; a CDR-L1 comprising the sequence set forth in any one of SEQ ID NOs: 19 and 22; a CDR- L2 comprising the sequence set forth in SEQ ID NO: 25 or the amino acid sequence DVS; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 30. In certain embodiments, the antibody, or antigen binding fragment thereof, further comprises a heavy chain constant region (e.g., an IgGl constant region) comprising LALA / YTE substitutions. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain comprising a heavy chain constant region selected from SEQ ID NO: 61 and SEQ ID NO: 173. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain comprising a heavy chain constant region set forth in SEQ ID NO: 173. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a humanAOJ-012PCAOE-0106WO lambda light chain constant region (e.g., a lambda light chain constant region of subtype 1, 2, 3, or 7, such as a lambda light chain constant region set forth in any one of SEQ ID NOs: 495-498). In some embodiments, the antibody, or antigen binding fragment thereof, comprises a constant light chain sequence comprising a sequence set forth in SEQ ID NO: 495.

[0340] Although the antibody may be produced using a polynucleotide sequence that encodes a constant heavy chain region containing a C-terminal lysine {e.g., a sequence encoding any one of SEQ ID NOs: 159-270), the C-terminal lysine may be cleaved off during manufacture or after administration (resulting in, e.g., an antibody containing a constant heavy chain sequence of any one of SEQ ID NOs: 47-158). Accordingly, any of the antibodies or antigen binding fragments thereof described above may comprise a human IgG sequence containing a C-terminal lysine {e.g., any one of SEQ ID NOs: 159-270), a human IgG sequence lacking a C-terminal lysine {e.g., any one of SEQ ID NOs: 40-158), or a mixture thereof {e.g., a mixture of the same heavy chain constant region sequence with and without a C-terminal lysine, such as a mixture of SEQ ID NO: 173 and SEQ ID NO: 61).

[0341] In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this disclosure are referred to herein as “variants” or “clones”. In some embodiments, such variants or clones are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants or clones are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.Anti-IL-13 Antibodies

[0342] The present application provides antibodies or antigen binding fragments thereof and compositions comprising an antibody, or an antigen binding fragment thereof, which binds IL-13. See also PCT Publication No. WO2023245187 and U.S. Patent Application Publication No. US20250129150, each of which is incorporated herein by reference in its entirety. In some embodiments, an anti-IL-13 antibody, or an antigen binding fragment thereof, described herein is selected from an anti-IL-13 antibody described therein.

[0343] In some embodiments, an anti-IL-13 antibody, or an antigen binding fragment thereof, described herein is selected from lebrikizumab, tralokinumab, romilkimab,AOJ-012PCAOE-0106WO cendakimab, and anrukinzumab or a variant thereof comprising an Fc region with one or more amino acid substitutions as described herein. In some embodiments, lebrikizumab comprises a variable heavy (VH) chain sequence having the amino acid sequence of SEQ ID NO: 289 and a variable light (VL) chain sequence having the amino acid sequence of SEQ ID NO: 290. In some embodiments, lebrikizumab comprises a heavy chain having the amino acid sequence of SEQ ID NO: 491 and a light chain sequence having the amino acid sequence of SEQ ID NO: 492. In some embodiments, tralokinumab comprises a heavy chain having the amino acid sequence of SEQ ID NO: 295 and a light chain sequence having the amino acid sequence of SEQ ID NO: 296, or a VH and / or VL therein (e.g., a VH having the sequence of SEQ ID NO: 518 and a VL having the sequence of SEQ ID NO: 519). In some embodiments, romilkimab comprises a heavy chain having the amino acid sequence of SEQ ID NO: 297 and a light chain sequence having the amino acid sequence of SEQ ID NO: 298, or a VH and / or VL therein. In some embodiments, cendakimab comprises a heavy chain having the amino acid sequence of SEQ ID NO: 299 and a light chain sequence having the amino acid sequence of SEQ ID NO: 300, or a VH and / or VL therein (e.g., a VH having the sequence of SEQ ID NO: 520 and a VL having the sequence of SEQ ID NO: 521). Tn some embodiments, anrukinzumab comprises a heavy chain having the amino acid sequence of SEQ ID NO: 301 and a light chain sequence having the amino acid sequence of SEQ ID NO: 302, or a VH and / or VL therein (e.g., a VH having the sequence of SEQ ID NO: 522 and a VL having the sequence of SEQ ID NO: 523).

[0344] Sequences of exemplary anti-IL-13 antibodies, or antigen binding fragments thereof, are provided in TABLE 7.TABLE 7. Sequences of IL-13 antibody constructs - VH, VL, and associated CDRsAOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOAOJ-012PCAOE-0106WOAnti- IL-13 VH Domains

[0345] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence set forth in SEQ ID NO: 286.

[0346] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the VH sequence provided in SEQ ID NO: 286. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence provided in SEQ ID NO: 286, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, theAOJ-012PCAOE-0106WO antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.Anti- IL- 13 VL Domains

[0347] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VL sequence selected from any one of SEQ ID NOs: 287-288.

[0348] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in any one of SEQ ID NOs: 287-288. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VL sequence provided in any one of SEQ ID NOs: 287-288, with up to 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.Anti- IL-13 VH-VL Combinations

[0349] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence set forth in SEQ ID NO: 286; and a VL sequence selected from any one of SEQ ID NOs: 287-288.

[0350] In certain aspects, SEQ ID NO: 286 can be combined with any one of SEQ ID NOs: 287-288.

[0351] In certain aspects, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence and a VL sequence of a construct provided in TABLE 7 orAOJ-012PCAOE-0106WO a VH sequence and a VL sequence of a construct provided in PCT Publication No. WO2023245187 and U.S. Patent Application Publication No. US20250129150, which are incorporated by reference herein in their entirety. In certain aspects, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence and a VL sequence from Table 2 in PCT Publication No. WO2023245187 and U.S. Patent Application Publication No. US20250129150 (e.g., a VH sequence and a VL sequence from the same row of Table 2).

[0352] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 286; and a VL sequence having at least about 80%. 90%. 91%. 92%. 93%. 94%. 95%. 96%. 97%, 98%, or 99% identity to a VL sequence provided in any one of SEQ ID NOs: 287-288. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises a VH sequence provided in SEQ ID NO: 286 with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions, and a VL sequence provided in any one of SEQ ID NOs: 287-288, with up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

[0353] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

[0354] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 288.

[0355] In certain embodiments of any of the antibodies, or antigen binding fragments thereof, described above, the antibody further comprises a heavy chain comprising a human IgG sequence selected from a sequence set forth in SEQ ID NO: 47-270. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chainAOJ-012PCAOE-0106WO comprising a human IgG sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain comprising a human IgG sequence set forth in SEQ ID NO: 173.

[0356] In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287; and the antibody further comprises a heavy chain comprising a human IgG sequence selected from a sequence set forth in any of SEQ ID NOs: 47-270. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain comprising a human IgG sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173. In certain embodiments, the antibody, or antigen binding fragment thereof, comprises a heavy chain comprising a human IgG sequence set forth in SEQ ID NO: 173. In certain embodiments of any of the antibodies, or antigen binding fragments thereof, described above, the antibody further comprises a constant light chain sequence comprising a sequence set forth in SEQ ID NO: 46.

[0357] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a heavy chain constant region (e.g., an IgGl constant region) comprising LALA / YTE substitutions, and a human kappa light chain constant region. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 286; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 287, a heavy chain constant region (e.g., an IgGl constant region) comprising LALA / YTE substitutions, and a human kappa light chain constant region. In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 286; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 287, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173 or a sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%AOJ-012PCAOE-0106WO identity to SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46 or a sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 46.

[0358] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46. In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 486 or 487 and a light chain sequence set forth in SEQ ID NO: 488. In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 486 and a light chain sequence set forth in SEQ ID NO: 488. The heavy chain sequence of SEQ ID NO: 486 contains a C-terminal lysine, which may be cleaved off during manufacture or after administration, resulting in an antibody containing the heavy chain sequence of SEQ ID NO: 487.

[0359] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a heavy chain constant region comprising YTE substitutions, and a human kappa light chain constant region. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 79 or SEQ ID NO: 191, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 286; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 287, a heavy chain constant region comprising YTE substitutions, and a human kappa light chain constant region. In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 286; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 287, a heavy chain constantAOJ-012PCAOE-0106WO region comprising a sequence set forth in SEQ ID NO: 79 or SEQ ID NO: 191 or a sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 79 or SEQ ID NO: 191, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46 or a sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 46.

[0360] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 79 or SEQ ID NO: 191, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46.

[0361] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a heavy chain constant region (e.g., an IgGl constant region) comprising LALA / LS substitutions, and a human kappa light chain constant region. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 180 or SEQ ID NO: 68, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 286; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 287, a heavy chain constant region (e.g., an IgGl constant region) comprising LALA / LS substitutions, and a human kappa light chain constant region. In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 286; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 287, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 180 or SEQ ID NO: 68 or a sequence having at least about 80%, 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 180 or SEQ ID NO: 68, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46 or a sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 46.

[0362] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 287, a heavy chain constant regionAOJ-012PCAOE-0106WO comprising a sequence set forth in SEQ ID NO: 180 or SEQ ID NO: 68, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46.

[0363] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 288, a heavy chain constant region (e.g., an IgGl constant region) comprising LALA / YTE substitutions, and a human kappa light chain constant region. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 288, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 286; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 288, a heavy chain constant region (e.g., an IgGl constant region) comprising LALA / YTE substitutions, and a human kappa light chain constant region. In certain embodiments, the antibody comprises a VH sequence having at least about 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VH sequence provided in SEQ ID NO: 286; and a VL sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a VL sequence provided in SEQ ID NO: 288, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173 or a sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46 or a sequence having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 46.

[0364] In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 288, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 61 or SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46. In certain embodiments, the antibody comprises a VH sequence set forth in SEQ ID NO: 286, a VL sequence set forth in SEQ ID NO: 288, a heavy chain constant region comprising a sequence set forth in SEQ ID NO: 173, and a light chain constant region comprising a sequence set forth in SEQ ID NO: 46.AOJ-012PCAOE-0106WO

[0365] Although the antibody may be produced using a polynucleotide sequence that encodes a constant heavy chain region containing a C-terminal lysine (e.g., a sequence encoding any one of SEQ ID NOs: 159-270), the C-terminal lysine may be cleaved off during manufacture or after administration (resulting in, e.g., an antibody containing a constant heavy chain sequence of any one of SEQ ID NOs: 47-158). Accordingly, any of the antibodies or antigen binding fragments thereof described above may comprise a human IgG sequence containing a C-terminal lysine (e.g., any one of SEQ ID NOs: 159-270), a human IgG sequence lacking a C-terminal lysine (e.g., any one of SEQ ID NOs: 40-158), or a mixture thereof (e.g., a mixture of the same heavy chain constant region sequence with and without a C-terminal lysine, such as a mixture of SEQ ID NO: 173 and SEQ ID NO: 61).Anti- IL-13 CDRs

[0366] In some embodiments, disclosed herein is an antibody, or antigen binding fragment thereof, comprising 1, 2, 3, 4, 5, or 6 of the CDRs of TABLE 7. In some embodiments, disclosed herein is an antibody, or antigen binding fragment thereof, comprising 6 of the Kabat CDRs of TABLE 7, 6 of the Chothia CDRs of TABLE 7, or 6 of the IMGT CDRs of TABLE 7. In some embodiments, the antibody, or an antigen binding fragment thereof, comprises 6 of the Kabat CDRs, 6 of the Chothia CDRs, or 6 of the IMGT CDRs from a single row of TABLE 7 (e.g., 6 CDRs from the same antibody).

[0367] In some embodiments, disclosed herein is an antibody, or an antigen binding fragment thereof, comprising 1, 2, 3, 4, 5, or 6 of the CDRs of an antibody provided in PCT Publication No. WO2023245187 and U.S. Patent Application Publication No.US20250129150, each incorporated by reference herein in its entirety. In some embodiments, disclosed herein is an antibody, or an antigen binding fragment thereof, comprising 1, 2, 3, 4, 5, or 6 of the Kabat CDRs of an antibody provided in PCT Publication No. WO2023245187. In some embodiments, disclosed herein is an antibody, or an antigen binding fragment thereof, comprising 1, 2, 3, 4, 5, or 6 of the Chothia CDRs of an antibody provided in PCT Publication No. WO2023245I87. In some embodiments, disclosed herein is an antibody, or an antigen binding fragment thereof, comprising 1 , 2, 3, 4, 5, or 6 of the IMGT CDRs of an antibody provided in PCT Publication No. WO2023245187. In some embodiments, the antibody, or an antigen binding fragment thereof, comprises 6 of the Kabat CDRs, 6 of the Chothia CDRs, or 6 of the IMGT CDRs from a single antibody described in Tables 3-8 ofAOJ-012PCAOE-0106WOPCT Publication No. WO2023245187 and U.S. Patent Application Publication No. US20250129150.

[0368] In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises one to three CDRs of a VH domain set forth in SEQ ID NO: 286. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises two to three CDRs of a VH domain set forth in SEQ ID NO: 286. In some embodiments, an antibody, or antigen binding fragment thereof, provided herein comprises three CDRs of a VH domain set forth in SEQ ID NO: 286. In some aspects, the CDRs are Kabat CDRs. In some aspects, the CDRs are Chothia CDRs. In some aspects, the CDRs are IMGT CDRs. In some aspects, the CDRs are AbM CDRs. In some aspects, the CDRs are Contact CDRs.

[0369] In some embodiments, the CDRs are CDRs having at least about 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to a CDR-H1, CDR-H2, or CDR-H3 selected from SEQ ID NOs: 273-280. In some embodiments, the CDR-H1 is a CDR-H1 of a VH domain set forth in SEQ ID NO: 286, with up to 1, 2, 3, 4, or 5 amino acid substitutions. In some embodiments, the CDR-H2 is a CDR-H2 of a VH domain set forth in SEQ ID NO: 286, with up to 1 , 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the CDR-H3 is a CDR-H3 of a VH domain set forth in SEQ ID NO: 286, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some aspects, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as “variants.” In some embodiments, such variants are derived from a sequence provided herein, for example, by affinity maturation, site directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. In some embodiments, such variants are not derived from a sequence provided herein and may, for example, be isolated de novo according to the methods provided herein for obtaining antibodies.

[0370] In some embodiments, an antibody, or antigen binding fragment there...

Claims

AOJ-012PCAOE-0106WOCLAIMS1. A composition comprising an isolated antibody, or antigen binding region thereof, that binds Thymic stromal lymphopoietin (TSLP), an isolated antibody, or antigen binding region thereof, that binds interleukin (IL)-13, and a hyaluronidase or variant thereof.

2. A composition comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL-13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding region thereof, that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10: a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27.

3. A composition comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL-13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding region thereof, that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41.

4. A composition comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL- 13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding region thereof, that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

5. A composition comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL- 13,AOJ-012PCAOE-0106WO and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding region thereof, that binds IL-13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

6. A composition comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL- 13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding region thereof, that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antibody, or antigen binding region thereof, that binds IL- 13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

7. A composition comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL- 13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding region thereof, that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41 ; and wherein the antibody, or antigen binding region thereof, that binds IL- 13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

8. A composition comprising hyaluronidase or variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL- 13,AOJ-012PCAOE-0106WO wherein the antigen binding region that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3: a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antigen binding region that binds IL- 13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR- L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

9. A composition comprising hyaluronidase or variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL-13, wherein the antigen binding region that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41; and wherein the antigen binding region that binds IL- 13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

10. A combination comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL- 13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding region thereof, that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-LI comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antibody, or antigen binding region thereof, that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising theAOJ-012PCAOE-0106WO sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

11. A combination comprising an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL- 13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding region thereof, that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41; and wherein the antibody, or antigen binding region thereof, that binds IL- 13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

12. A combination comprising hyaluronidase or variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL-13, wherein the antigen binding region that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antigen binding region that binds IL-13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR- L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.AOJ-012PCAOE-0106WO13. A combination comprising hyaluronidase or variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL-13, wherein the antigen binding region that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41; and wherein the antigen binding region that binds IL- 13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

14. A method of treating an inflammatory disorder or disease in a human patient comprising administering to the patient an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL- 13, and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding region thereof, that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21 ; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antibody, or antigen binding region thereof, that binds IL- 13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

15. A method of treating an inflammatory disorder or disease in a human patient comprising administering to the patient an isolated antibody, or antigen binding region thereof, that binds TSLP, an isolated antibody, or antigen binding region thereof, that binds IL-1 , and a hyaluronidase or variant thereof, wherein the antibody, or antigen binding region thereof, that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41; andAOJ-012PCAOE-0106WO wherein the antibody, or antigen binding region thereof, that binds IL-13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

16. A method of treating an inflammatory disorder or disease in a human patient comprising administering to the patient hyaluronidase or variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL-13, wherein the antigen binding region that binds TSLP comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 3; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 10: a CDR-H3 comprising the sequence set forth in SEQ ID NO: 13; a CDR-L1 comprising the sequence set forth in SEQ ID NO: 21; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 26; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 27, and wherein the antigen binding region that binds IL- 13 comprises a CDR-H1 comprising the sequence set forth in SEQ ID NO: 273; a CDR-H2 comprising the sequence set forth in SEQ ID NO: 276; a CDR-H3 comprising the sequence set forth in SEQ ID NO: 279; a CDR- L1 comprising the sequence set forth in SEQ ID NO: 281; a CDR-L2 comprising the sequence set forth in SEQ ID NO: 283; and a CDR-L3 comprising the sequence set forth in SEQ ID NO: 285.

17. A method of treating an inflammatory disorder or disease in a human patient comprising administering to the patient hyaluronidase or variant thereof and a multi-specific antibody comprising a first antigen binding region that binds TSLP and a second antigen binding region that binds IL- 13, wherein the antigen binding region that binds TSLP comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41; and wherein the antigen binding region that binds IL- 13 comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287.

18. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody, or antigen bindingAOJ-012PCAOE-0106WO region thereof, that binds TSLP and / or the antibody, or antigen binding region thereof, that binds IL- 13 is a humanized, human, or chimeric antibody.

19. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody, or antigen binding region thereof, that binds TSLP and / or the antibody, or antigen binding region thereof, that binds IL- 13 is a humanized antibody.

20. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 comprises a heavy chain human constant region of a class selected from IgG, IgA, IgD, IgE, and IgM.

21. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL-13 comprises a human Fc region, and wherein the human Fc region comprises a human heavy chain constant region of the class IgG and a subclass selected from IgGl, IgG2, IgG3, and IgG4.

22. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 comprises a human IgGl Fc region.

23. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 comprises a human IgG4 Fc region.

24. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding regionAOJ-012PCAOE-0106WO that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 comprises a human IgG2 Fc region.

25. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 comprises a human IgGl Fc region with LALA and YTE mutations.

26. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP comprises a human IgGl Fc region with LALA mutations (L239A / L240A by direct numbering) and YTE mutations (M257Y / S259T / T261E by direct numbering) and the antibody or antigen binding region that binds IL-13 comprises a human IgGl Fc region with LALA mutations (L235A / L236A by direct numbering) and YTE mutations (M253Y / S255T / T257E by direct numbering) .

27. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 comprises an Fc region that binds to Neonatal Fc receptor (FcRn).

28. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL-13 comprises an Fc region that binds an FcRn with higher affinity at pH 6.0 compared to an antibody comprising a wild-type Fc region.

29. The composition of any one of claims 1-9, the combination of any one of claims 10-1 , or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL- 13 comprises an Fc region that binds to FcRn with a KD of < 1 x 10’7M at pH 6.0.AOJ-012PCAOE-0106WO30. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP and / or the antibody or antigen binding region that binds IL-13 is a monoclonal antibody.

31. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP binds a TSLP sequence set forth in any one of the amino acid sequences of SEQ ID NOs: 271-272.

32. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds IL-13 binds an IL-13 sequence set forth in SEQ ID NO: 291 or SEQ ID NO: 292.

33. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP comprises a heavy chain comprising a constant heavy chain sequence set forth in SEQ ID NO: 61 or 173.

34. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP comprises a light chain comprising a constant light chain sequence set forth in SEQ ID NO: 495.

35. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds TSLP comprises a heavy chain comprising a constant heavy chain sequence set forth in SEQ ID NO: 61 or 173 and a light chain comprising a constant light chain sequence set forth in SEQ ID NO: 495.

36. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding regionAOJ-012PCAOE-0106WO that binds IL- 13 comprises a heavy chain comprising a constant heavy chain sequence set forth in SEQ ID NO: 61 or 173.

37. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds IL- 13 comprises a light chain comprising a constant light chain sequence set forth in SEQ ID NO: 46.

38. The composition of any one of claims 1-9, the combination of any one of claims 10-13, or the method of any one of claims 14-17, wherein the antibody or antigen binding region that binds IL- 13 comprises a heavy chain comprising a constant heavy chain sequence set forth in SEQ ID NO: 61 or 173 and a light chain comprising a constant light chain sequence set forth in SEQ ID NO: 46.

39. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the hyaluronidase is a recombinant human hyaluronidase.

40. The composition, combination, or method of claim 39, wherein the recombinant human hyaluronidase comprises the amino acid sequence set forth in any one of SEQ ID NOs: 419-428 and 430-485.

41. The composition, combination, or method of claim 39, wherein the recombinant human hyaluronidase is rHuPH20.

42. The composition, combination, or method of claim 41, wherein the rHuPH20 formulation is ENHANZE®.

43. The combination of any one of claims 10-13 or the method of any one of claims 14-17, wherein the hyaluronidase and antibody or antibodies are administered in separate formulations.AOJ-012PCAOE-0106WO44. The combination or method of claim 43, wherein the hyaluronidase and antibody or antibodies are administered simultaneously in separate formulations.

45. The combination or method of claim 43, wherein the hyaluronidase is administered to the patient prior to administration of the antibody or antibodies.

46. The combination or method of claim 43, wherein the hyaluronidase is administered to the patient after administration of the antibody or antibodies.

47. The combination or method of claim 43, wherein the hyaluronidase is administered to the patient after administration of one of the antibodies, but before administration of the other antibody.

48. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the hyaluronidase and antibody or antibodies are administered in a single formulation.

49. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the hyaluronidase and antibody or antibodies are administered by subcutaneous injection.

50. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the hyaluronidase and antibody or antibodies are administered by intravenous injection.

51. The composition of any one of claims 1-9, the combination of any one of claims 10- 13, or the method of any one of claims 14-17, wherein the hyaluronidase is rHuPH20 administered at a concentration of 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21 ,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000, 30,000, 31,000, 32,000, 33,000, 34,000, 35,000, 36,000, 37,000, 38,000, 39,000, or 40,000 units.AOJ-012PCAOE-0106WO52. The method of any one of claims 14-17, wherein the inflammatory disorder or disease is atopic dermatitis.

53. The method of claim 52, wherein the treatment reduces disease severity in the patient and wherein disease severity is assessed by an atopic dermatitis disease severity outcome measure.

54. The method of any one of claims 14-17, wherein the inflammatory disorder or disease is asthma; chronic sinusitis with nasal polyps; Chronic Rhinosinusitis without Nasal Polyps (CRSsNP); eosinophilic esophagitis (EoE); an Eosinophilic gastrointestinal disorder or disease (EGID) selected from the group consisting of Eosinophilic Gastritis (EoG), Eosinophilic Enteritis (EoN), Eosinophilic Colitis (EoC), and Eosinophilic Gastroenteritis (EGE); Churg-Strauss syndrome / Eosinophilic granulomatosis with polyangiitis (EGPA);Prurigo Nodularis (PN); Chronic Spontaneous Urticaria (CSU); Chronic Pruritis of Unknown Origin (CPUO); Bullous Pemphigoid (BP); Cold Inducible Urticaria (ColdU); Allergic Fungal Rhinosinusitis (AFRS); Allergic Bronchopulmonary Aspergillosis (ABPA); Chronic Obstructive Pulmonary Disease (COPD); Crohn’s disease; lupus; rheumatoid arthritis (RA); psoriasis; ulcerative colitis; hidradenitis suppurativa; celiac disease; idiopathic pulmonary fibrosis; alopecia areata; or systemic sclerosis.

55. A kit for treating an inflammatory disorder or disease in a human patient, the kit comprising:(a) a dose of an antibody, or antigen binding fragment thereof, that binds TSEP, wherein the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 34 and a VL sequence set forth in SEQ ID NO: 41 ;(b) a dose of an antibody, or antigen binding fragment thereof, that binds IL- 13, wherein the antibody, or antigen binding fragment thereof, comprises a VH sequence set forth in SEQ ID NO: 286 and a VL sequence set forth in SEQ ID NO: 287;(c) a dose of a hyaluronidase or variant thereof; and(d) instructions.

56. The kit of claim 55, wherein the hyaluronidase is a recombinant human hyaluronidase.AOJ-012PCAOE-0106WO57. The kit of claim 56, wherein the recombinant human hyaluronidase comprises the amino acid sequence set forth in any one of SEQ ID NOs: 419-428 and 430-485.

58. The kit of claim 56, wherein the recombinant human hyaluronidase is rHuPH20.

59. The kit of claim 58, wherein the rHuPH20 formulation is ENHANZE®.

60. The kit of claim 55, for use in treating an inflammatory disorder or disease.

61. The kit of claim 60, wherein the inflammatory disorder or disease is atopic dermatitis.

62. The kit of claim 60, wherein the inflammatory disorder or disease is asthma; chronic sinusitis with nasal polyps; Chronic Rhinosinusitis without Nasal Polyps (CRSsNP); eosinophilic esophagitis (EoE); an Eosinophilic gastrointestinal disorder or disease (EGID) selected from the group consisting of Eosinophilic Gastritis (EoG), Eosinophilic Enteritis (EoN), Eosinophilic Colitis (EoC), and Eosinophilic Gastroenteritis (EGE); Churg-Strauss syndrome / Eosinophilic granulomatosis with polyangiitis (EGPA); Prurigo Nodularis (PN); Chronic Spontaneous Urticaria (CSU); Chronic Pruritis of Unknown Origin (CPUO); Bullous Pemphigoid (BP); Cold Inducible Urticaria (ColdU); Allergic Fungal Rhinosinusitis (AFRS); Allergic Bronchopulmonary Aspergillosis (ABPA); Chronic Obstructive Pulmonary Disease (COPD); Crohn disease; lupus; rheumatoid arthritis (RA); psoriasis; ulcerative colitis; hidradenitis suppurativa; celiac disease; idiopathic pulmonary fibrosis; alopecia areata: or systemic sclerosis.

Images